

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 629 624 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
23.04.2003 Bulletin 2003/17

(51) Int Cl.7: **C07D 413/12, C07D 413/14,
C07D 417/12, A61K 31/41,
A61K 31/44**

(21) Application number: **94304225.9**

(22) Date of filing: **10.06.1994**

(54) **Tetrazole derivatives, their production and use**

Tetraderivate, ihre Herstellung und Verwendung

Dérivés de tétrazole, leur préparation et leur utilisation

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **11.06.1993 JP 14090693**

(43) Date of publication of application:
21.12.1994 Bulletin 1994/51

(73) Proprietor: **TAKEDA CHEMICAL INDUSTRIES,
LTD.
Chuo-ku, Osaka 541 (JP)**

(72) Inventors:
• **Sohda, Takashi
Osaka 569 (JP)**
• **Ikeda, Hitoshi
Osaka 578 (JP)**
• **Momose, Yu
Hyogo 665 (JP)**

(74) Representative: **Wright, Robert Gordon McRae
Elkington & Fife,
Prospect House,
8 Pembroke Road
Sevenoaks, Kent TN13 1XR (GB)**

(56) References cited:
EP-A- 0 310 370 US-A- 4 845 231

- **JOURNAL OF MEDICINAL CHEMISTRY, vol.33,
1990 pages 240 - 245 J.H. MUSSE ET AL.
'N-[(Arylmethoxy)phenyl] Carboxylic ...'**
- **JOURNAL OF MEDICINAL CHEMISTRY, vol.33,
1990 pages 1186 - 1194 R.D. YOUSSEFYEH ET
AL. 'Development of a Novel Series ...'**
- **JOURNAL OF MEDICINAL CHEMISTRY, vol.33,
1990 pages 2828 - 2841 R.A. GALEMMO, JR., ET
AL. 'The Development of a Novel Series ...'**
- **JOURNAL OF MEDICINAL CHEMISTRY, vol.35,
no.14, 1992 pages 2617 - 2626 T. SOHDA ET AL.
'Studies on Antidiabetic Agents. 11. ...'**
- **CHEMICAL AND PHARMACEUTICAL BULLETIN,
vol.39, no.6, 1991 pages 1440 - 1445 Y. MOMOSE
ET AL. 'Studies on Antidiabetic Agents. X. ...'**
- **JOURNAL OF MEDICINAL CHEMISTRY, vol.35,
no.5, 1992 pages 944 - 953 K.L. KEES ET AL.
'Perfluorocarbon-Based Antidiabetic Agents'**

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 0 629 624 B1

Description

[0001] This invention relates to a novel tetrazole derivative having an action of lowering blood sugar and lipid in blood, and to an agent comprising it for the therapy of diabetes and hyperlipemia, which is useful in the field of pharmaceuticals.

[0002] As remedies of diabetes, various biguanide compounds and sulfonylurea compounds have so far been used. However, biguanide compounds are hardly used at present, since they cause lactic acidosis, while sulfonylurea compounds, which have a strong action of lowering blood sugar, often cause severe hypoglycemia, requiring special attention in use. Tetrazole derivatives having substituents at 5-position have also been known. For example, in Journal of Medicinal Chemistry, 35, p.944 (1992), there is disclosed that a series of 5-substituted tetrazole derivatives possess blood glucose lowering activity. These compounds, however, are not satisfactory in their activity.

[0003] US Patent No. 4,845,231 discloses compounds of the formula:



in which

R is a substituted or unsubstituted monocyclic or bicyclic alkyl group containing from 3 to 8 ring carbon atoms, wherein any substituent is alkyl of 1 to 3 carbon atoms, oxo, hydroxy, carboxy or when the hydroxy and carboxy substituents taken together they form a 1,3-carbonyloxy lactone ring closed structure;

n is one of the integers 0, 1, 2 or 3;

X is —O—,




or —SO₂NH—; and


Z is =CH- or -N=;

or a pharmaceutically acceptable salt thereof, are antihyperglycemic agents.

EP-A-0,310,370 discloses compounds having the formula



and their pharmaceutically acceptable salts where



Y is $-\overset{\text{R}^4}{\underset{|}{\text{C}}}=\text{N}-$, $-\text{N}=\overset{\text{R}^4}{\underset{|}{\text{C}}}-$, $-\overset{\text{R}^4}{\underset{|}{\text{C}}}=\overset{\text{R}^4}{\underset{|}{\text{C}}}-$, $-\text{S}-$ or $-\overset{\text{R}^4}{\underset{|}{\text{N}}}-$;

Z is $-(\text{CH}_2)_n\text{O}-$, $-(\text{CH}_2)_n\text{S}-$, $-(\text{CH}_2)_n\overset{\text{R}^4}{\underset{|}{\text{N}}}-$,



$-\overset{\text{O}}{\parallel}{\text{C}}-\overset{\text{R}^4}{\underset{|}{\text{N}}}-$, $-(\text{CH}_2)_n\overset{\text{O}}{\parallel}{\text{S}}-$, $-(\text{CH}_2)_n\text{SO}_2-$;

$-\overset{\text{R}^4}{\underset{|}{\text{C}}}=\overset{\text{R}^4}{\underset{|}{\text{C}}}-$ or $-\text{C}\equiv\text{C}-$;

R¹ is $-(\text{CH}_2)_n\overset{\text{R}^4}{\underset{|}{\text{N}}}-\text{SO}_2\text{R}^5$, $-\overset{\text{OR}^4}{\text{CH}}\text{CH}_2\overset{\text{R}^4}{\underset{|}{\text{N}}}-\text{R}^6$,


$-(\text{CH}_2)_n-\overset{\text{O}}{\parallel}{\text{C}}-\overset{\text{R}^4}{\underset{|}{\text{N}}}-\text{SO}_2\text{R}^5$,

$-(\text{CHR}^7)_n\overset{\text{O}}{\parallel}{\text{C}}-\text{OR}^4$, $-(\text{CHR}^7)_n\overset{\text{O}}{\parallel}{\text{C}}-\overset{\text{R}^4}{\underset{|}{\text{N}}}-\text{OR}^4$, $-(\text{CH}_2)_n-\overset{\text{O}}{\parallel}{\text{C}}-\text{NHNH}_2$,




each meaning of n is independently 0-5;

each meaning of R² is independently hydrogen, loweralkyl, loweralkoxy, lower alkoxycarbonyl, trifluoromethyl, nitro, cyano or halo; R³ is



or




W represents a bond or -O-, -S- or




m is 1-15;

each meaning of R^4 is independently hydrogen or loweralkyl;

R^5 is loweralkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or



R^6 is hydrogen, lower alkyl, $-COOR^4$ or



and


R^7 is hydrogen or methyl.

[0004] The compounds are useful as anti-allergic and antiinflammatory agents.

[0005] A number of prior art references exist which provide relevant background art and which develop new compounds as high-affinity leukotriene receptor antagonists.

[0006] The article by John H. Musser et al, entitled "N-[(Arylmethoxy)phenyl] Carboxylic Acids, Hydroxamic Acids, Tetrazoles, and Sulfonyl Carboxamides. Potent Orally Active Leukotriene D_4 Antagonists of Novel Structure", J. Med. Chem., 1990, 33, pages 240-245, discloses four series of N-[(arylmethoxy)phenyl] compounds as leukotriene D_4 antagonists. Most relevant to the present invention is the development of N-[(arylmethoxy)phenyl] tetrazoles.


[0007] The article by Raymond D. Youssefyeh et al, entitled "Development of a Novel Series of (2-Quinolinylmethoxy) phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 1. Initial Structure-Activity Relationships", J. Med. Chem., 1990, 33, pages 1186-1194, discloses orally active, highly potent, specific antagonists of the peptidoleukotrienes containing a (2-quinolinylmethoxy)phenyl moiety. A later article appearing in the same Journal at pages 2828-2841, by Robert A. Galemmo et al, entitled "The Development of a Novel Series of (Quinolin-2-ylmethoxy) phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 3. Structural Variation of the Acidic Side Chain To Give Antagonists of Enhanced Potency" also discloses the development of orally active sulfidopeptide leukotriene antagonists containing a (quinolin-2-ylmethoxy)phenyl moiety. In particular, this reference discloses 5-tetrazole compounds:



[0008] The present inventors made an extensive search for 5-substituted tetrazole derivatives possessing more potent activity of lowering blood glucose and lipid in blood, resulting in that, in the substituent at the 5-position, introduction of phenyl group or pyridyl group substituted with alkoxy group having an optionally substituted heterocyclic residue serves to remarkably enhance the activity, thus accomplishing the present invention.


[0009] More specifically, the present invention relates to:

(1) a compound of the formula:



wherein n denotes an integer of 1 to 3;


A is an aromatic 5-membered cyclic residue shown by the formula:



wherein B¹ is S, O or NR (wherein R is hydrogen, a C₁₋₃ alkyl group or an aralkyl group selected from benzyl or phenethyl); B² is N or C-R² (R² is hydrogen or a C₁₋₅ alkyl group optionally substituted with hydroxyl group; R¹ is hydrogen; hydrocarbon residue selected from C₁₋₈ saturated aliphatic hydrocarbon residues, C₂₋₈ unsaturated aliphatic hydrocarbon residues, C₃₋₇ saturated alicyclic hydrocarbon residues, C₅₋₇ unsaturated alicyclic hydrocarbon residues, C₄₋₉ alicyclic-aliphatic hydrocarbon residues, C₇₋₉ aromatic-aliphatic hydrocarbon residues, aromatic hydrocarbon residues, selected from phenyl and naphthyl; or a heterocyclic residue selected from a 5- or 6-membered ring which contains, besides carbon atoms, 1 to 3 atoms selected from N, O and S as atoms constituting the ring, which is bonded through a carbon atom; wherein, when the hydrocarbon residue contains an alicyclic group or when the heterocyclic residue is a saturated one, each of them may have 1 to 3 C₁₋₃ alkyl groups on the ring thereof; and when the hydrocarbon residue contains an aromatic group or when the heterocyclic residue is an unsaturated one, it may have 1 to 4 substituents selected from halogen, hydroxyl, cyano, nitro, trifluoromethyl, a C₁₋₄ alkoxy group, a C₁₋₄ alkyl group, a C₂₋₄ alkoxy carbonyl group, a C₁₋₃ alkylthio and a C₁₋₄ alkylamino group; Y is -CH₂CH₂CH₂- or -CH₂CH₂CH₂CH₂-; and X is CH or N, or a pharmaceutically acceptable salt thereof.

(2) an agent for the therapy of diabetes or hyperlipemia, which contains, as an effective component, a tetrazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof; and

(3) a method of producing a tetrazole derivative represented by the formula (I), which comprises allowing a compound of the formula:



wherein each symbol is of the same meaning as defined above to react with a metal azide compound.

[0010] In the formula (I), it is preferable that benzene ring or pyridine ring is substituted with A-(CH₂)_n-O- at para-position relative to the attaching point of -Y-.

[0011] In the above-mentioned formulae (I) and (II), the heterocyclic residue shown by A is an oxazolyl (2-oxazolyl, 4-oxazolyl), or thiazolyl (2-thiazolyl, 4-thiazolyl).

[0012] These heterocyclic residues may optionally have one or more substituents on optional positions of the ring.

Examples of the substituents include hydrocarbon residues, heterocyclic residues or amino group, which may optionally have further substituents.

[0013] Said hydrocarbon residues include aliphatic hydrocarbon residues, alicyclic hydrocarbon residues, alicyclic-aliphatic hydrocarbons, aromatic-aliphatic hydrocarbon residues and aromatic hydrocarbon residues. Examples of said aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 8 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.butyl, t.butyl, pentyl, isopentyl, neopentyl, t.pentyl, hexyl, isohexyl, heptyl and octyl; and C_{2-8} unsaturated aliphatic hydrocarbon residues having 2 to 8 carbon atoms such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1-heptenyl, 1-octenyl, ethynyl, 1-propinyl, 2-propinyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexadiynyl, 5-hexynyl, 1-heptynyl and 1-octynyl. Among them, aliphatic hydrocarbons having at most 4 carbon atoms are preferable. Examples of said alicyclic hydrocarbon residue include saturated alicyclic hydrocarbon residues having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; and C_{5-7} unsaturated alicyclic hydrocarbon residues having 5 to 7 carbon atoms such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3-cycloheptenyl and 2,4-cycloheptadienyl. Among them alicyclic hydrocarbon residues having 5 or 6 carbon atoms are preferable. Examples of the alicyclic-aliphatic hydrocarbon residues include, among those formed by bondage of the above-mentioned alicyclic hydrocarbon residues and aliphatic hydrocarbon residues, ones having 4 to 9 carbon atoms such as cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3-cyclopentenylmethyl, cyclohexylmethyl, 2-cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl and cycloheptylethyl. Examples of said aromatic aliphatic hydrocarbon residues include phenyl alkyls having 7 to 9 carbon atoms such as benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and 1-phenylpropyl; and naphthyl alkyl having 11 to 13 carbon atoms such as α -naphthylmethyl, α -naphthylethyl, β -naphthylmethyl and β -naphthylethyl. And, examples of said aromatic hydrocarbon residue include phenyl and naphthyl (α -naphthyl, β -naphthyl).

[0014] The said heterocyclic group is a 5- or 6-membered ring which contains, besides carbon atoms, 1 to 3 atoms selected from N, O and S as atoms constituting the ring, which is bonded through carbon atom. Specific examples of the heterocyclic group include heterocyclic groups such as thienyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), imidazolyl (2-imidazolyl, 4-imidazolyl, 5-imidazolyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl and 6-pyridazinyl); and a saturated heterocyclic group such as piperidinyl (2-piperidinyl, 3-piperidinyl, 4-piperidinyl), pyrrolidinyl (2-pyrrolidinyl, 3-pyrrolidinyl), morpholinyl (2-morpholinyl), and tetrahydrofuryl (2-tetrahydrofuryl, 3-tetrahydrofuryl etc.).

[0015] The amino group may be substituted. As substituted amino group, mention is made of N-mono-substituted amino group and N,N-disubstituted amino group.

[0016] "N-mono-substituted amino group" means an amino group having one substituent. Examples of the substituent include a lower alkyl group (e.g. one having 1 to 4 carbon atoms such as methyl, ethyl, propyl, butyl, isobutyl, t. butyl, etc.), cycloalkyl group (e.g. one having 3 to 7 carbon atoms such as cyclopentyl, cyclohexyl, etc.), aryl group (e.g. phenyl, naphthyl, etc.), aromatic heterocyclic group (e.g. pyridyl, thienyl, furyl, oxazolyl, thiazolyl, etc.), non-aromatic heterocyclic group (e.g. piperidinyl, pyrrolidinyl, morpholinyl, etc.), aralkyl group (e.g. benzyl, phenethyl, etc.), acyl group (e.g. acetyl, propionyl, etc.), carbamoyl group, N-mono-substituted carbamoyl group (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, etc.), N,N-disubstituted carbamoyl group (e.g. N,N-dimethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-diethylcarbamoyl, etc.), a lower alkoxycarbonyl group (e.g. one having 2 to 5 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.), hydroxyl group, a lower alkoxy group (e.g. one having 1 to 4 carbon atoms such as methoxy, ethoxy, propoxy, butoxy, etc.) and aralkyloxy group (e.g. benzyloxy, phenethyloxy, naphthyloxy, etc.).


[0017] "N,N-di-substituted amino group" means amino groups having two substituents. Examples of the substituents include, on one hand, those of substantially the same ones as in the above-mentioned "N-mono-substituted amino group", while, examples of the other hand include alkyl group, cycloalkyl group, aryl group and aralkyl group. And, in some instances, the two substituents may form a cyclic amino group taken together with nitrogen atom. Examples of such cyclic amino group include 1-azetidino, 1-pyrrolidino, piperidino, morpholino, piperazino and piperazino having, at the 4-position, e.g. a lower alkyl group (e.g. one having 1 to 4 carbon atoms such as methyl, ethyl, propyl, etc.), an aralkyl group (e.g. benzyl, phenethyl, naphthylmethyl, etc.) or an aryl group (e.g. phenyl, naphthyl, etc.).

[0018] The above-mentioned hydrocarbon residue and heterocyclic ring residue as the substituents on the heterocyclic residue A may have a substituent or substituents at their optional positions. When the hydrocarbon residue contains an alicyclic group or when the heterocyclic ring residue is a saturated one, each of them may have a one to 3 lower alkyl groups having 1 to 3 carbon atoms (e.g. methyl, ethyl, propyl and isopropyl) on the ring thereof (including N atoms). And, when the hydrocarbon residue contains an aromatic hydrocarbon residue or when the heterocyclic group is an unsaturated one, it may have 1 to 4 substituents which are the same as or different from one another.

Examples of these substituents include halogen (fluorine, chlorine, iodine), hydroxyl, cyano, nitro, trifluoromethyl, a lower alkoxy group (e.g. ones having 1 to 4 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy and butoxy), a lower alkyl group (e.g. ones having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl and butyl), a lower alkoxy-carbonyl group (e.g. ones having 2 to 4 carbon atoms such as methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl), a lower alkylthio (e.g. ones having 1 to 3 carbon atoms such as methylthio, ethylthio, propylthio and isopropylthio), and a lower alkylamino group (e.g. one having 1 to 4 carbon atoms such as methylamino, ethylamino and dimethylamino).

[0019] When the heterocyclic residue shown by A has two or more hydrocarbon residues as substituents thereof, and when these hydrocarbon residues are located at mutually adjacent positions on the aromatic 5-membered heterocyclic ring, they may be combined together to form a condensed ring. This means that the two hydrocarbon residues are bonded to each other to form a saturated or unsaturated di-valent linear hydrocarbon residue having 3 to 5 carbon atoms. Specific examples of the linear hydrocarbon residue include $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CHCH}_2-$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-$ and $-\text{CH}=\text{CH}-\text{CH}_2\text{CH}_2\text{CH}_2-$.


[0020] Among the heterocyclic residues shown by A, those represented by the formula:



{wherein B^1 is a sulfur atom, an oxygen atom or a NR group [wherein R stands for hydrogen, a lower alkyl group (e.g. ones having 1 to 3 carbon atoms such as methyl and ethyl) or an aralkyl group (e.g. benzyl group and phenethyl)]; and B^2 is a nitrogen atom or $\text{C}-\text{R}^2$ (R^2 is hydrogen or a lower alkyl group optionally substituted with hydroxyl group); R^1 is hydrogen, an optionally substituted hydrocarbon residue or heterocyclic residue; provided that R^1 and R^2 may be combined with each other to form a condensed ring if R^1 is combined with one of ring-constituting carbon atoms adjacent to the carbon atom on which R^2 is substituted.} are preferable. The hydrocarbon residue, heterocyclic residue shown by R^1 and substituents of these groups are the same as those described above referring to aromatic 5-membered heterocyclic residue.

[0021] The lower alkyl group shown by R^2 is exemplified by ones having 1 to 5 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, t-butyl and pentyl, with preference given to those having 1 to 3 carbon atoms. Although this alkyl group may have a hydroxyl group at an optional position, the α -position is especially preferred. When B^2 is $\text{C}-\text{R}^2$ and R^2 is hydrogen, the ring may be substituted with R^1 at the position of B^2 . This heterocyclic residue is bonded through a relevant atom on the ring, and the group bonded through the carbon atom adjacent to nitrogen atom is preferable. For example, when B^1 is NR, B^2 is $\text{C}-\text{R}^2$, and R^2 is hydrogen, a group (III) bonded through B^2 is also a preferable example.

[0022] Among the heterocyclic groups represented by the above formula, especially thiazolyl or oxazolyl represented by the formula:



[wherein R^1 and R^2 have the meanings given above; each of R^3 and R^4 is hydrogen, an optionally substituted hydrocarbon residue or an optionally substituted heterocyclic residue, and they may form a condensed ring by bonding to each other; and B is an oxygen atom or sulfur atom] is preferable. The hydrocarbon residue or heterocyclic residue shown by R^3 or R^4 and substituents thereof are the same as those described above referring to an aromatic 5-membered heterocyclic ring residue. R^3 and R^4 may form a condensed ring, which is the same as the condensed ring formed by an aromatic 5-membered heterocyclic ring residue having two hydrocarbon residues as substituents at mutually adjacent positions.

[0023] The ring having X as a component atom is a benzene ring when X is CH, while it is a pyridine ring when X is N. It is preferable that X is CH. The symbol n denotes an integer of 1 to 3, preferably 1 or 2. The divalent hydrocarbon residue shown by Y is 1,3-propylene or 1,4-butylene.

[0024] The compound (I) of this invention is a compound having acidic nitrogen on its tetrazole ring or having a basic nitrogen when it has a pyridine ring, thus involving basic and acid salts. As these salts, pharmaceutically acceptable one are preferable, which are exemplified by salts with inorganic bases, salts with organic bases, salts with organic acids and salts with basic or acidic amino acids. Preferable examples of salts with inorganic bases include alkali metal salts such as sodium salt or potassium salt; alkaline earth metal salts such as calcium salt or magnesium salt; as well as aluminum salt and ammonium salt. Preferable examples of salts with organic bases include those with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine or N,N-dibenzylethylenediamine. Preferable examples of salts include those with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid or phosphoric acid. Preferable examples of salts with organic acids include those with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid. Preferable examples of salts with basic amino acid include salts with arginine, lysine or ornithine, and, preferable examples of salts with acidic amino acid include salts with aspartic acid or glutamic acid.

[0025] The compound (I) or its pharmaceutically acceptable salts of this invention have hypoglycemic activity and low toxicity. For example, when the compound of Example 1 was orally administered to mice at 15 mg/kg for 4 days, no changes occurred in body weight or liver weight, in comparison with the control. And, oral administration of the compound produced in Example 14 at a dose of 100 mg/kg or intraperitoneal administration at a dose of 50 mg/kg killed no test animals. The compounds of this invention can be used for mammals including man as therapeutic agents of diabetes and hyperlipemia. The compound (I) can be administered orally or non-orally as solid compositions such as tablets, capsules, granules or powders; or liquid compositions such as syrup or injections, prepared by formulating with pharmaceutically acceptable carriers.

[0026] As pharmaceutically acceptable carriers, use is made of conventional organic or inorganic carriers for pharmaceutical preparations, more specifically, for example, excipients, lubricants, binders and disintegrators for solid preparations; and solvents, solubilizers, suspending agents, isotonicizers, buffering agents and local anesthetic agents. And, upon necessity, such additives as antiseptics, anti-oxidants, colorants and sweeteners are further used. Preferable examples of excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose and light silicon dioxide. Preferable examples of lubricants include magnesium stearate, calcium stearate, talc and colloid silica. Preferable examples of binders include crystalline cellulose, sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone. Preferable examples of disintegrators include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, cross carmellose sodium and carboxymethyl starch sodium. Preferable examples of solvents include distilled water for injection, alcohol, propylene glycol, macrogol, sesame oil and corn oil. Preferable examples of solubilizers include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris-amino methane, cholesterol, triethanolamine, sodium carbonate and sodium citrate. Preferable examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glycerine monostearate; and hydrophilic polymers such as poly (vinyl alcohol), polyvinylpyrrolidone, carboxymethyl cellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose and hydroxypropylcellulose. Preferable examples of isotonicizers include sodium chloride, glycerine and D-mannitol. Preferable examples of buffering agents include buffer solutions of phosphates, acetates, carbonates and citrates. Preferable examples of local anesthetic agents include benzyl alcohol. Preferable examples of antiseptics include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid. Preferable examples of anti-oxidants include sulfites and ascorbic acid.

[0027] Concerning the method of administration, the compound (I) is normally used orally in the form of, for example, tablets, capsules (including soft capsules and microcapsules), powders and granules, but, as the case may be, it can be administered non-orally in the form of, for example, injectable preparations, suppositories and pellets. Daily dose for oral administration in adults ranges from 0.05 to 10 mg/kg/, preferably divided into one to three doses daily.

[0028] The following is the description of the method of producing the compound (I) of this invention.

(Method A)


[0029] By allowing a nitrile derivative (II) to react with an azide compound, a tetrazole derivative (I) is produced. The reaction from (II) to (I) is conducted by, for example, in accordance with the method described on the Journal of American Chemical Society, 80, p.3908 (1958), allowing (II) to react with sodium azide-ammonium chloride in N,N-dimethylformamide. The respective amounts of ammonium chloride and sodium azide range from 1 to 7 moles, preferably from 1 to 5 moles, relative to one mole of the compound (II). This reaction is carried out at temperatures ranging from 50°C to 180°C for 1 to 50 hours. And, the reaction from (II) to (I) can also be conducted by, for example, in accordance with the method described on the Journal of Organic Chemistry 56, p.2395 (1991), allowing the compound (II) to react with trimethyltin azide or tributyltin azide, followed by treatment with an acid.

[0030] The tetrazole derivatives and their salts thus obtained can be isolated and purified by known means of sep-

aration and purification such as concentration, concentration under reduced pressure, crystallization, recrystallization, phasic transfer and chromatography.

(Method B)

[0031]



[wherein Y¹ is an unsaturated divalent hydrocarbon residue, Y² is a saturated divalent hydrocarbon residue, and other symbols are of the same meaning as defined above.]

[0032] The unsaturated divalent hydrocarbon residue shown by Y¹ is unsaturated one shown by Y, and the saturated divalent hydrocarbon residue shown by Y² is saturated one shown by Y.




[0033] In this method, the compound (I-1) among the compounds produced by Method A is subjected to reduction to produce the compound (I-2). While this reduction reaction can be conducted by a *per se* known method, it is carried out advantageously by catalytic hydrogenation using a metal catalyst. This catalytic hydrogenation is carried out, in accordance with a conventional method, in a solvent in the presence of a catalyst under hydrogen atmosphere of 1 to 150 atmospheric pressure. Examples of the solvent includes alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol, aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as ethyl ether, isopropyl ether, dioxane and tetrahydrofuran, halogenated hydrocarbons such as chloroform, dichloromethane and 1,1,2,2-tetrachloroethane, ethyl acetate, acetic acid or a mixture of these solvents. As the catalyst, use is made of, for example, a transition metal such as palladium, platinum or rhodium to proceed the reaction advantageously. The reaction temperatures range from 0 to 100°C, preferably 10 to 80°C, and the reaction time ranges from 0.5 to 50 hours.

[0034] Thus-obtained tetrazole derivatives and salts thereof can be isolated and purified by means of conventional means such as concentration, concentration under reduced pressure, crystallization, recrystallization, phasic transfer and chromatography.

[0035] The nitrile derivatives (II) employed as the starting materials in the method of this invention can be produced by, for example, the following manner.

(Method C)

[0036]



[in the formula (IV), Z stands for a halogen atom, in the formula (VIII-1), Q stands for a leaving group, and other symbols are of the same meaning as defined above].

[0037] As the halogen atom shown by Z, mention is made of fluorine, chlorine, bromine and iodine. As the leaving group shown by Q, mention is made of, for example, besides halogen atoms including chlorine, bromine and iodine, methanesulfonyloxy and p-toluenesulfonyloxy, among others.

[0038] The production steps comprising condensation of the compound (III) with the compound (IV) to give the compound (V), which is then led to the aldehyde derivative (VI-1), are conducted in accordance with the methods described in, for example, the Chemical and Pharmaceutical Bulletin, 39, p.1440 (1991) and the Journal of Medicinal Chemistry, 35, p.2617 (1992).

[0039] Then, the compound (VI-1) is subjected to reduction to produce the alcohol compound (VII-1). This reduction can be conducted by a *per se* known method, for example, reduction by using a metal hydride, reduction by using a metal hydride complex, reduction by using diborane and a substituted borane and catalytic hydrogenation. In other words, this reaction is carried out by processing the compound (VI-1) with a reducing agent. Examples of the reducing agent include a metal hydride complex such as alkali metal borohydride (e.g. sodium borohydride and lithium borohydride); a metal hydride complex such as lithium aluminum hydride; a metal hydride such as sodium hydride; a metal or a metal salt such as an organotin compound (e.g. triphenyltin hydride), a nickel compound and a zinc compound; a catalytic reduction agent using a transition metal catalyst such as palladium, platinum and rhodium, and hydrogen; and diborane, among others. This reaction is conducted in an organic solvent which does not affect on the reaction. As the solvent, use is made of by adequately selecting, depending of kinds of the reducing agent, from, for example, aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane; ethers such as diethyl ether, tetrahydrofuran and dioxane; alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; amides such as N,N-dimethylformamide; or a mixture of these solvents. The reaction temperatures range from -20°C to 150°C, especially preferably from 0°C to 100°C. The reaction time ranges from about 1 to 24 hours.




[0040] Then, the compound (VII-1) is allowed to react with a halogenating agent or a sulfonylating agent to produce the compound (VIII-1). As the halogenating agent, use is preferably made of, for example, hydrochloric acid, thionyl chloride and phosphorus tribromide, and in this case, the compound (VIII-1), wherein Q stands for chlorine or bromine, is produced. This reaction is conducted in an adequate inert solvent (e.g. benzene, toluene, xylene, chloroform and dichloromethane) or by using an excess amount of a halogenating agent as the solvent at temperatures ranging from -10 to 80°C. The amount of the halogenating agent to be employed ranges from 1 to 20 mol. relative to the compound (VII-1). As the sulfonylating agent, use is preferably made of, for example, methanesulfonyl chloride, p-tosyl chloride and benzenesulfonyl chloride, to produce the compound (VIII-1) wherein Q stands for methanesulfonyloxy, p-tolue-

nesulfonyloxy and benzenesulfonyloxy, respectively. This reaction is conducted in an adequate inert solvent (e.g. benzene, toluene, xylene, ethyl ether, ethyl acetate, tetrahydrofuran, chloroform and dichloromethane) in the presence of a base (e.g. triethylamine, N-methyl morpholine, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium carbonate and potassium carbonate) at temperatures ranging from -10 to 30°C. The amounts of the sulfonylating agent and the base range from 1 to 2 mol. relative to 1 mol. of the compound (VII-1), respectively. By allowing 1 mol. of the compound (VIII-1), wherein Q stands for chlorine, bromine or sulfonyloxy, to react with 1 to 1.5 mol. of sodium iodide or potassium iodide, the compound (VIII-1), wherein Q stands for iodine, can also be produced. In this case, the reaction can be conducted in a solvent such as acetone, methyl ethyl ketone, methanol and ethanol at temperatures ranging from 20 to 80°C. Then, by allowing the compound (VIII-1) to react with potassium cyanide or sodium cyanide to produce the compound (II-1). The reaction is conducted usually in a solvent (e.g. ether, tetrahydrofuran, dioxane, chloroform, dichloromethane, 1,2-dichloroethane, methanol, ethanol, ethyl acetate, acetone, 2-butanone, N,N-dimethylformamide and dimethyl sulfoxide) at temperatures ranging from 0°C to 100°C. The amount of potassium cyanide or sodium cyanide to be employed ranges from 1 to 8 mol. relative to 1 mol. of the compound (VIII-1).

[0041] The nitrile derivative (II-1) thus obtained can be isolated and purified by means of a conventional isolating and purifying procedures, for example, concentration, concentration under reduced pressure, crystallization, recrystallization, phasic transfer and chromatography.

(Method D)

[0042]



[wherein J is a hydrogen or a lower alkyl group, R⁵ stands for a lower alkyl group, q denotes 0 or 1 and other symbols are of the same meaning as defined above.]

[0043] Examples of the lower alkyl group shown by J or R⁵ include ones having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl and butyl etc.







[0044] In this method, an aldehyde derivative (VI-2) is allowed to react with a cyanomethylphosphonic acid ester derivative (IX) to produce an unsaturated nitrile derivative (II-2). The reaction of (VI-2) with (IX) is conducted, in accordance with a conventional manner, in an adequate solvent in the presence of a base. Examples of the solvent include aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as dioxane, tetrahydrofuran and dimethoxyethane; alcohols such as methanol, ethanol and propanol; N,N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane and a mixture of these solvents. Examples of the base include alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate and sodium hydrogencarbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline; metal hydrides such as sodium hydride and potassium hydride; sodium ethoxide, sodium methoxide and potassium t-butoxide, and

the amount of these bases to be employed ranges from 1 to 5 mol. equivalents relative to the compound (VI-2). The amount of the compound (IX) to be employed ranges from 1 to 5 mol. equivalents, preferably from about 1 to 3 mol. equivalents, relative to the compound (VI-2). This reaction is conducted usually at temperatures ranging from -50°C to 150°C, preferably from about -10 to 100°C. The reaction time ranges from 0.5 to 30 hours. By subjecting the compound (II-2) thus obtained to reduction, the compound (II-3) is produced. This reduction is conducted in substantially the same manner as in Method B.

[0045] The nitrile derivatives thus obtained can be isolated and purified by means of a conventional isolating and purifying procedures such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phasic transfer and chromatography.

[Method E]

[0046]



[wherein R⁶ and R⁷ independently stand for a lower alkyl group; q denotes 0 or 1; and other symbols are of the same meaning as defined above.]

[0047] Examples of the lower alkyl group shown by R⁶ and R⁷ include ones having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl and butyl etc.


[0048] In this method, at first, an aldehyde or a ketone derivative (VI-3) is allowed to react with a phosphonoacetic acid derivative or γ -phosphonocrotonic acid derivative (X) to produce an unsaturated ester derivative (XI). The reaction of (VI-3) with (X) is carried out in substantially the same manner as in the reaction of the compound (VI-2) with (IX) in Method D. Then, the compound (XI) is subjected to reduction to produce the alcohol derivative (VII-2). This reduction reaction can be carried out by a *per se* known method as exemplified by reduction with a metal hydride, reduction with a metal hydride complex and reduction with diborane and substituted borane. In other words, this reaction is conducted by processing the compound (XI) with a reducing agent. As the reducing agent, mention is made of, for example, a metal hydride complex such as alkali metal borohydride (e.g. sodium borohydride and lithium borohydride) and lithium aluminum hydride, and diborane, and the reaction is more advantageously carried out by using diisobutylaluminum hydride. This reaction is carried out in an organic solvent which does not exert influence on the reaction. As the solvent, use is made of by adequately selecting, depending of kinds of the reducing agent, from, for example, aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane; ethers such as diethyl ether, tetrahydrofuran and dioxane; alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; amides such as N,N-dimethylformamide; or a mixed solvent of them. The reaction temperatures range from -20°C to 150°C, especially preferably from 0°C to 100°C. The reaction time ranges from about 1 to 24 hours. Then, by subjecting the compound (VII-2) to reduction, the compound (VII-3) is produced. This reduction reaction is carried out in substantially the same manner as in Method B. The compound (VII-3) is processed, in substantially the same manner as in Method C comprising leading the compound (VII-1) to (VIII-1) and further to (II-1), to produce the nitrile derivative (II-4).

[0049] The nitrile derivatives thus obtained can be isolated and purified by conventional isolating and purifying means such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer and chromatography.

[0050] The pyridine aldehyde derivatives (VI-4) to be employed in Method D and Method E can be produced in accordance with, for example, Method F.

[Method F]

[0051]




[in the formula (XV), Z' stands for chlorine, bromine or iodine, and other symbols are of the same meaning as defined above.]

[0052] In this method, at first, 2-chloro-5-nitropyridine (XII) is allowed to react with the alcohol derivative (III) to produce the compound (XIII). The reaction of (XII) with (III) is conducted, in accordance with a conventional method, in an adequate solvent in the presence of a base. Examples of the solvent include aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as dioxane, tetrahydrofuran and dimethoxyethane; N,N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane; and a mixture solvent of them. Examples of the base include alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate and sodium hydrogencarbonate; amines such as pyridine, triethylamine, and N,N-dimethyl aniline; metal hydrides such as sodium hydride and potassium hydride; potassium t-butoxide, etc., and the amount of these bases to be employed is preferably about 1 to 5 mol. equivalents relative to the compound (III). This reaction is carried out usually at temperatures ranging from -50°C to 150°C, preferably from about -10°C to 100°C. The reaction time ranges from 0.5 to 30 hours. Then the compound (XIII) is subjected to reduction to produce the amine derivative (XIV-1). While this reduction can be carried out by a *per se* known method, it is advantageously carried out by catalytic hydrogenation using a metal catalyst. This catalytic hydrogenation is carried out, in accordance with a conventional method, in a solvent in the presence of a catalyst under hydrogen atmosphere of 1 to 150 atm. Examples of the solvent include alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as ethyl ether, isopropyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as chloroform, dichloromethane and 1,1,2,2-tetrachloroethane; ethyl acetate, acetic acid; or a mixed solvent of them. Use of, as the catalyst, for example, a metal such as a nickel compound, and a transition metal catalyst such as palladium, platinum and rhodium, serves to allow the reaction to proceed advantageously. The reaction temperatures range from 0 to 100°C, preferably from 10 to 80°C, and the reaction time ranges from 0.5 to 50 hours. Then, the compound (XIV-1) is subjected to a *per se* known the Sandmeyer reaction to produce the halogen derivative (XV). In this reaction, at first, the compound (XIV-1) is diazotized by adding dropwise thereto an aqueous solution of sodium nitrite (NaNO₂) in a solvent in the presence of hydrochloric acid, hydrobromic acid or hydroiodic acid, which is then allowed to react with an aqueous solution of sodium halide or potassium halide to produce the compound (XV). Examples of the solvent include alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; ethers such as dioxane and tetrahydrofuran; acetone, 2-butanone, or a mixed solvent of them. The reaction temperatures range from -80°C to 100°C, preferably from -50 to 60°C, and the reaction time ranges from 0.5 to 50 hours. Then, the compound (XV) is processed with, for example, butyllithium, tert.butyllithium, methylolithium, phenyllithium or phenylmagnesium bromide to give a lithio compound, which is then allowed to react with N,N-dimethylformamide (DMF) to produce the compound (VI-4).

(Method G)

[0053]




[in the formulae (XVI-1) and (II-5), G stands for cyano group (CN) or COOR⁷; and other symbols are of the same meaning as defined above.]

[0054] The reaction from the compound (XIV-2) to the compound (XVI-1) is conducted in accordance with the method described in the Journal of Medicinal Chemistry, 35, p.2617 (1992). More specifically, the compound (XIV-2) is subjected to so called Meerwein arylation reaction, which comprises diazotizing the compound (XIV-2) in the presence of hydrohalogenic acid (HZ'), which is further allowed to react with acrylic acid ester (CH₂=CHCOOR⁷) or acrylonitrile (CH₂=CH-CN) in the presence of a copper catalyst (e.g. copper (I) oxide, copper (II) oxide, copper (I) chloride, copper (II) chloride,

copper (I) bromide and copper (II) bromide). Then, the compound (XVI-1) is subjected to dehydrohalogenation to produce the compound (II-5). This dehydrohalogenation reaction is conducted in an adequate solvent in the presence of a base. Examples of the solvent include aromatic hydrocarbon such as benzene, toluene and xylene; ethers such as dioxane, tetrahydrofuran and dimethoxyethane; alcohols such as methanol, ethanol and propanol; ethyl acetate, acetonitrile, pyridine, N,N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, acetone and 2-butanone; and a mixed solvent of them. Examples of the base include inorganic bases such as alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide), alkaline earth metal hydroxide (e.g. magnesium hydroxide and calcium hydroxide), alkali metal carbonate (e.g. sodium carbonate and potassium carbonate), alkaline earth metal carbonate (e.g. magnesium carbonate and calcium carbonate), alkali metal hydrogencarbonate (sodium hydrogencarbonate and potassium hydrogencarbonate) and alkali metal acetate (sodium acetate and potassium acetate); and organic bases such as trialkylamine (e.g. trimethylamine and triethylamine), picoline, N-methylpyrrolidine, N-methylmorpholine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]non-5-ene and 1,8-diazabicyclo[5,4,0]-7-undecene. The amount of these bases to be employed ranges preferably from about 1 to 5 mol. equivalents relative to the compound (XVI-1). This reaction is carried out usually at temperatures ranging from -20°C to 150°C, preferably from about -10°C to 120°C.

(Method H)

[0055]








[wherein each symbol is of the same meaning as defined above.]

[0056] In this method, α -halogenopropionitrile derivative (XVI-2) is subjected to reduction to produce the propionitrile derivative (II-6). This method can be carried out by, for example, catalytic reduction in substantially the same manner as in Method B, or a conventional method using zinc or iron and acetic acid.

(Method I)

[0057]



[wherein each symbol is of the same meaning as defined above.]


[0058] In this method, at first, the compound (VI-2) and a cyanoacetic acid ester derivative are subjected to condensation to produce the compound (XVII). This condensation reaction is carried out in a solvent in the presence of a base. Examples of the solvent include alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as ethyl ether, isopropyl ether, dioxane and tetrahydrofuran; pyridine, N,N-dimethylformamide, dimethyl sulfoxide and acetic acid. Examples of the base to be employed include sodium alkoxide (e.g. sodium methoxide and sodium ethoxide), potassium carbonate, sodium carbonate, sodium hydride, sodium acetate, or secondary amines such as piperazine, pyrrolidine, morpholine, diethyl-

amine and diisopropylamine, etc.. The amount of the base to be used ranges from 0.01 to 5 molar equivalents, preferably from 0.05 to 2 molar equivalents relative to the compound (VI-2). This reaction is carried out at temperatures ranging from 0 to 150°C, preferably from 20 to 120°C for a period ranging from 5 to 30 hours. Then, the compound (XVII) is subjected to reduction to produce the compound (XVIII). This reduction reaction can be carried out by a per se known method, for example, reduction using a metal hydride, reduction using a metal hydride complex or catalytic hydrogenation. In other words, this reaction is carried out processing the compound (XVII) with a reducing agent. Examples of the reducing agent include a metal hydride complex such as alkali metal borohydride (e.g. sodium borohydride and lithium borohydride); a metal hydride complex such as lithium aluminum hydride; a metal hydride such as sodium hydride; a metal or a metal salt such as an organotin compound (e.g. triphenyltin hydride), a nickel compound and a zinc compound; a catalytic reduction agent using a transition metal catalyst such as palladium, platinum and rhodium, and hydrogen; and diborane, among others. Above all, use of alkali metal borohydride (e.g. sodium borohydride and lithium borohydride) serves to allow the reaction to proceed advantageously. This reaction is conducted in an organic solvent which does not affect on the reaction. As the solvent, use is made of by adequately selecting, depending of kinds of the reducing agent, from, for example, aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane; ethers such as diethyl ether, tetrahydrofuran and dioxane; alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; amides such as N,N-dimethylformamide; or a mixture of these solvents. The reaction temperatures range from -20°C to 150°C, especially preferably from 0°C to 100°C. The reaction time ranges from about 1 to 24 hours. Then, the compound (XVIII) is subjected to hydrolysis, which is then subjected to decarboxylation to produce the compound (II-3). This hydrolysis is carried out, in accordance with a per se known method, in an aqueous solvent in the presence of an acid or a base. The carboxylic acid derivative (XIX) thus obtained is subjected to decarboxylation, after isolation or without isolation, to produce the compound (II-3). This decarboxylation reaction is carried out in a solvent with heating. Examples of the solvent include aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane; ethers such as diethyl ether, tetrahydrofuran and dioxane; alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; amides such as N,N-dimethylformamide; chlorobenzene, o-dichlorobenzene and pyridine; or a mixed solvent of them. The reaction temperatures ranges from 50°C to 250°C, especially preferably from 70°C to 160°C. The reaction time ranges from about 1 to 24 hours.

[0059] A nitrile derivative can also be produced by method J or method K.


(Method J)

[0060]



[wherein each symbol has the meaning given above]

[0061] In this method, a nitrile derivative (II-5) can be produced by the reaction of a compound (XX) with a compound (XXI). The method is carried out in a suitable solvent in the presence of a base. The solvents include aromatic hydrocarbons such as benzene, toluene, xylene, etc. ethers such as dioxane, tetrahydrofuran, dimethoxyethane, etc., alcohols such as methanol, ethanol, propanol, etc. halogenated hydrocarbons such as chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, etc., N,N-dimethylformamide, dimethyl sulfoxide, or a mixture of two or more selected from these solvents. As the base, alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogencarbonate, etc., amines such as pyridine, triethylamine, N,N-dimethylaniline, etc., metal hydride such as sodium hydride, potassium hydride, etc., metal alkoxide such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc. are mentioned. The base is used in an amount of 1 to 5 mol per 1 mol of compound (II). This reaction is carried out at a temperature ranging from -50°C to 150°C, preferably -10°C to 100°C. The reaction time is usually 0.5 to 30 hours.



[0062] In this method, first a compound (XX) and a compound derivative (XXII) is reacted to give an ester derivative (XXIII). This reaction is carried out in a manner similar to that of a compound (XX) and a compound (XXI) in Method J. Then a compound (XIII) is converted to alcohol derivative (VII-4) by a manner similar to the reaction converting a compound (XI) to a compound (VII-2) in Method E. A compound (VII-4) is converted to a compound (VIII-3) by a manner similar to the reaction converting a compound (VII-3) to a compound (VIII-2) in Method E. A compound (VIII-3) is converted to a compound (II-6) by a manner similar to the reaction converting a compound (VIII-2) to a compound (II-4) in Method E.

[0063] The compound (I) of this invention has hypoglycemic and hypolipidemic actions. Experimental data supporting these actions are as follows.

Experimental Example

Hypoglycemic and hypolipidemic actions in mice

[0064] The test compound mixed with powdered diet (CE-2, Japan Clea) at a ratio of 0.01% or 0.005% was fed to KKAy mice (9-14 week old) for 4 days ad libitum. The animals had free access to water during this period. Blood was collected from the orbital venous plexus and the values of plasma glucose and triglyceride were respectively determined quantitatively by enzyme method using Iatrochem-GLU(A) and Iatro-MA701 TG kit (Iatron). The respective values are shown in terms of percent reduction compared to non-drug-dosed group, as shown in [Table 1].

[Table 1]

| Compound (Example No.) | Dose ¹⁾ | Hypoglycemic Action (%) | Hypolipidemic Action (%) |
|------------------------|--------------------|-------------------------|--------------------------|
| 1 | 0.01 | 45 | 28 |
| 2 | 0.01 | 21 | 9 |
| 3 | 0.01 | 15 | 26 |

¹⁾ Concentration (%) (w/w) of the test compound in diet.

[Table 1] (continued)

| Compound (Example No.) | Dose ¹⁾ | Hypoglycemic Action (%) | Hypolipidemic Action (%) |
|------------------------|--------------------|-------------------------|--------------------------|
| 5 | 0.01 | 26 | 10 |
| 7 | 0.01 | 36 | 37 |
| 8 | 0.01 | 38 | 32 |
| 9 | 0.01 | 31 | 33 |
| 14 | 0.005 | 53 | 74 |
| 16 | 0.005 | 43 | 48 |
| 22 | 0.005 | 46 | 85 |
| 23 | 0.005 | 26 | 23 |

¹⁾ Concentration (%) (w/w) of the test compound in diet.

[0065] As stated above, tetrazole derivatives (I) of the present invention exhibit excellent hypoglycemic and hypolipidemic action, and are useful as a therapeutic agent for diabetes mellitus, hyperlipemia, hypertension or the like.

Reference Example 1

[0066] To a solution of 2-chloro-5-nitropyridine (25 g) and 2-(5-methyl-2-phenyl-4-oxazolyl)ethanol (32.1 g) in THF (250 ml) was added, in small portions, sodium hydride (60% in oil, 6.92 g), and the mixture was stirred. The reaction mixture was stirred, at room temperature, for further 15 hours, which was poured into water, followed by extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure. The residual crystals are collected by filtration, followed by recrystallization from ethanol to afford 2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-nitropyridine (25.4 g, 49%) as yellowish brown crystals, m.p. 110.5-111.5°C.

Reference Example 2

[0067] A mixture of 2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-nitropyridine (13.4 g), palladium carbon (5%, 1.5 g) and ethyl acetate (200 ml) - methanol (150 ml) was subjected to catalytic hydrogenation at room temperature under 1 atmospheric pressure. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to leave crystals. The crystals were collected by filtration to obtain 5-amino-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (11.4 g, 93%), which was recrystallized from ethyl acetate - hexane to give brown crystals, m.p. 107-108°C.

Reference Example 3

[0068] To a mixture of 5-amino-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (10.0 g), conc. hydrochloric acid (8.47 ml) and acetone (100 ml) was added dropwise, at temperatures of 10°C or below, a solution of sodium nitrite (NaNO₂) (2.46 g) in water (10 ml). The mixture was stirred for 30 minutes at 10°C, to which was added dropwise a solution of potassium iodide (KI) (2.46 g) in water (10 ml). The reaction mixture was stirred for one hour at 30-35°C, and for one hour at 35-40°C, followed by concentration under reduced pressure. The residue was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure to leave an oily product, which was subjected to a silica gel column chromatography. From the fraction eluted with ethyl acetate - hexane (1:3, v/v), 5-iodo-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (7.22 g, 52%), which was recrystallized from ethyl acetate - hexane to yield colorless crystals, m.p. 105-106°C.

Reference Example 4

[0069] To a solution of 5-iodo-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (2.5 g) in tetrahydrofuran (40 ml) was added dropwise, at -65°C in nitrogen streams, a hexane solution of n-butyl lithium (1.6M, 4.61 ml). The mixture was stirred for 15 minutes at the same temperature, to which was added dropwise N,N-dimethylformamide (0.71 ml). The cooling bath was removed, and the reaction mixture was stirred for further 30 minutes, to which was added a saturated aqueous solution of ammonium chloride (6 ml). The reaction mixture was poured into water, which was

subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO_4), then the solvent was distilled off under reduced pressure to leave 5-formyl-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (1.5 g, 79%), which was recrystallized from ethyl acetate - hexane to give colorless crystals, m.p.99-100°C.

5 Reference Example 5

10 **[0070]** To a solution of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde (7.0 g) in ethanol (100 ml) was added, under ice-cooling, sodium borohydride (0.473 g), and the mixture was stirred for 2 hours at room temperature. To the reaction mixture was added acetic acid (2 ml), which was poured into ice-water, then resulting crystalline precipitate was collected by filtration, followed by recrystallization from ethyl acetate - hexane to yield 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl alcohol (6.9 g, 88%) as colorless plates, m.p.112-113°C.

Reference Example 6

15 **[0071]** To a solution of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl alcohol (6.8 g) in chloroform (100 ml) was added thionyl chloride (3.1 g), and the mixture was stirred for one hour at room temperature. The reaction mixture was washed with a saturated aqueous solution of sodium hydrogencarbonate and then water, followed by drying (MgSO_4). The solvent was distilled off to leave 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl chloride (6.5 g, 90%) as colorless needles, m.p.93-94°C.

20

Reference Example 7

25 **[0072]** A mixture of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl chloride (6.4 g), powdered potassium cyanide (4.0 g) and N,N-dimethylformamide (50 ml) was stirred for two hours at 60°C. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO_4), then the solvent was distilled off to leave 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl cyanide (5.2 g, 81%). The product was recrystallized from ethyl acetate - hexane to afford colorless needles, m.p.109-110°C.

Reference Example 8

30

35 **[0073]** Sodium hydride (60% in oil, 2.0 g) was added, in small portions at 0°C a solution of diethyl cyanomethylphosphonate (8.2 g) in tetrahydrofuran (150 ml). The mixture was stirred for about 15 minutes, to which was added 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde (13.0 g), and the mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into ice-water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO_4), then the solvent was distilled off to leave 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamitrile (11.8 g, 85%). The product was recrystallized from ethyl acetate - hexane to give colorless needles, m.p.112-113°C.

Reference Examples 9 to 15

40


[0074] In substantially the same manner as in Reference Example 8, compounds shown in [Table 2] were obtained.








45

50

55

Table 2



| Reference Example No. | A | n | Yield (%) | Melting point (°C) | Recrystallization Solvent |
|--------------------------|---|---|--------------|----------------------------|--|
| 9 |  | 2 | 79 | Note 1) oily product | _____ |
| 10 |  | 2 | 67 | 121-122 | ethyl acetate- hexane |
| 11 |  | 2 | 98 | 97- 98 | dichloromethane- isopropyl ether |
| 12 |  | 2 | 48 | 147-148 | dichloromethane- isopropyl ether |
| 13 |  | 1 | — | Note 2) | |
| 14 |  | 2 | 87 | Note 3) oily product | _____ |
| 15 |  | 1 | 76 | 97- 98 | ethyl acetate- hexane |

Note 1) Mixture of (E)- and (Z)-compound in a ratio of 3:1.

NMR(δ ppm in CDCl_3): 1.2-2.1(10H,m), 2.24(3H,s), 2.6-2.8(1H,m), 2.89(2H,t, \underline{J} =7Hz), 5.28(d, \underline{J} =12Hz) and 5.70(d, \underline{J} =16.5Hz)(total 1H), 6.88 and 6.91(total 2H, each d, \underline{J} =9Hz), 7.02(d, \underline{J} =12Hz) and 7.32(d, \underline{J} =16.5 Hz)(total 1H), 7.37 and 7.76(total 2H, each d, \underline{J} =9Hz)

Note 2) Used for the subsequent reaction without isolation

Note 3) Mixture of (E)- and (Z)-compound in a ratio of 5:2

NMR(δ ppm) in CDCl_3): 2.24(3H,s), 2.38(3H,s), 2.88(2H,t, \underline{J} =7Hz), 4.21 and 4.23(t, \underline{J} =7Hz)(total 2H), 5.28(d, \underline{J} =12Hz) and 5.71(d, \underline{J} =16.5Hz)(total 1H), 6.89 and 6.93(total 2H, each d, \underline{J} =9Hz), 7.02(d, \underline{J} =12Hz) and 7.32(d, \underline{J} =16.5Hz)(total 1H), 7.37 and 7.77(total 2H, each d, \underline{J} =9Hz).


Reference Example 16






[0075] A mixture of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamionitrile (4.0 g), palladium-carbon (5%, 0.5 g) and ethyl acetate (50 ml) was subjected to catalytic hydrogenation at room temperature under 1 atmospheric pressure. The catalyst was filtered off, then the filtrate was concentrated under reduced pressure to leave 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionitrile (3.7 g, 93%). The product was recrystallized from ethyl acetate - hexane to give colorless needles, m.p.109-110°C.

Reference Examples 17 to 21

[0076] In substantially the same manner as in Reference Example 16, compounds shown in [Table 3] were obtained.

[Table 3]



| Reference Example No. | A | n | Y | Yield (%) | Melting point (°C) | Recrystallization Solvent |
|-----------------------|---|---|------------------------------------|---------------|-------------------------|---------------------------------|
| 17 |  | 2 | -CH ₂ CH ₂ - | 79 | Note 1) oily product | — |
| 18 |  | 2 | -CH ₂ CH ₂ - | 77 | 116-117 | dichloromethane-isopropyl ether |
| 19 |  | 2 | -CH ₂ CH ₂ - | 93 | 79-80 | ethyl ether-hexane |
| 20 |  | 1 | -CH ₂ CH ₂ - | Note 2) 54 | Note 3) oily product | — |
| 21 |  | 2 | -CH ₂ CH ₂ - | quant. | 62-63 | acetone-hexane |

Note 1) NMR(δ ppm in CDCl₃): 1.2-2.1(10H,m),
 2.24(3H,s), 2.57(2H,t,J=7.5Hz),
 2.69(1H,tt,J=11.5,3.5Hz), 2.87(2H,t,J=7Hz),
 2.89(2H,t,J=7.5Hz), 4.14(2H,t,J=7Hz), 6.84(2H,d,J=8Hz),
 7.12(2H,d,J=8.5Hz)

Note 2) Overall yield from the corresponding benzaldehyde

Note 3) NMR(δ ppm in CDCl₃): 2.59(2H,t,J=7Hz),
 2.91(2H,t,J=7Hz), 3.55(3H,s), 5.00(2H,d,J=1Hz),
 6.46(1H,t,J=1Hz), 6.97(2H,d,J=8.5Hz),
 7.15(2H,d,J=8.5Hz), 7.2-7.5(5H,m).

Reference Example 22

[0077] Sodium hydride (60% in oil, 2.2 g) was added, in small portions at 0°C, to a solution of triethyl phosphonoacetate (11.2 g) in tetrahydrofuran (200 ml), and the mixture was stirred for 15 minutes at the same temperature. To the mixture was then added 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde (14.0 g), which was stirred for one hour at room temperature.

[0078] The reaction mixture was poured into ice-water, which was neutralized with 2N HCl. Resulting crystalline precipitate was collected by filtration, which was recrystallized from ethyl acetate - hexane to give ethyl 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-cinnamate (15.1 g, 88%).

Colorless needles, m.p.114-115°C.

Reference Example 23

[0079] A toluene solution of diisobutylaluminum hydride (1.5M, 67 ml) was added dropwise at 0°C to a suspension of ethyl 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamate (15.0 g) in toluene (200 ml).

[0080] The mixture was stirred for 2 hours at room temperature, to which was added 2N HCl (200 ml) under ice-cooling. The organic layer was washed with water, dried (MgSO₄) and concentrated to give (E)-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-propen-1-ol (12.0 g, 90%), which was recrystallized from ethyl acetate to give colorless prisms, m.p.127-128°C.

Reference Example 24

[0081] A mixture of (E)-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-propen-1-ol (3.1 g), palladium-carbon (5%, 0.5 g) and ethyl acetate (50 ml) was subjected to catalytic hydrogenation under 1 atmospheric pressure at room temperature. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to yield 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propan-1-ol (2.8 g, 90%), which was recrystallized from ethyl acetate - hexane to give colorless needles, m.p.99-100°C.

Reference Example 25

[0082] To a mixture of 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propan-1-ol (2.6 g) and benzene (50 ml) was added phosphorus tribromide (PBr₃) (2.1 g), which was stirred for 2 hours at 70°C. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off to leave 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl bromide (0.98 g, 32%), which was recrystallized from ethyl acetate - hexane to give colorless needles, m.p. 78-79°C.

Reference Example 26

[0083] To a mixture of 5-amino-2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]pyridine (9.1 g), an aqueous solution of HBr (47%, 14.2 ml) and acetone (150 ml) was added dropwise, at temperature not exceeding 10°C a solution of sodium nitrite (NaNO₂) (2.33 g) in water (10 ml). The mixture was stirred for 30 minutes at 10°C, to which was added acrylonitrile (CH₂=CHCN) (12.1 ml). To the mixture was added, while stirring vigorously, copper(I) oxide (Cu₂O) (0.1 g). The reaction mixture was stirred for further one hour at temperature ranging from 30 to 35°C, followed by concentration under reduced pressure. The concentrate was poured into water, which was made alkaline with a conc. ammonia water, followed by extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure. The residual oily product was subjected to a silica gel column chromatography. From the fractions eluted with ethyl acetate - hexane (1:1, v/v), was obtained 2-bromo-3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-pyridyl]propionitrile (6.11 g, 48%), which was recrystallized from ethyl acetate - hexane to give colorless crystals, m.p.93-94°C.

Reference Example 27

[0084] A mixture of 2-bromo-3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-pyridyl]propionitrile (2.0 g), palladium-carbon (5%, 0.2 g) and dioxane (30 ml) was subjected to catalytic reduction under 1 atmospheric pressure at room temperature. The catalyst was filtered off, then the filtrate was concentrated under reduced pressure. The concentrate was subjected to a silica gel column chromatography. From the fractions eluted with ethyl acetate - hexane (2:3, v/v), was obtained 3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-pyridyl]propionitrile (1.3 g, 78%), which was recrystal-

lized from ethyl acetate - hexane to give colorless crystals, m.p.105-106°C.

Reference Example 28

- 5 **[0085]** A mixture of 2-bromo-3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-pyridyl]propionitrile (4.5 g), lithium bromide (LiBr) (1.14 g), lithium carbonate (Li₂CO₃) (2.17 g) and N,N-dimethylformamide (50 ml) was stirred for 2.5 hours at 120°C. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure to leave (E)-3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-pyridyl]acrylonitrile (3.2, 89%), which was recrystallized
10 from ethyl acetate - hexane to give pale yellow crystals, m.p.116-117°C.

Reference Example 29

- 15 **[0086]** A mixture of 4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]benzaldehyde (2.0 g), ethyl cyanoacetate (0.795 g), piperidine (0.15 g) and pyridine (30 ml) was stirred for 2 hours at 100-110°C. The reaction mixture was poured into water. Resulting crystalline precipitate was collected by filtration and recrystallized from dichloromethane-ethanol to give ethyl 4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-cyanocinnamate (2.45 g, 96%) as colorless needles, m.p.120-121°C.

20 Reference Example 30

- [0087]** To a mixture of ethyl 4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-α-cyanocinnamate (2.25 g) and dioxane (30 ml) - ethanol (30 ml) was added sodium borohydride (0.06 g) under ice-cooling. The mixture was stirred for one hour at the same temperature. The reaction mixture was poured into ice-water, which was made acid and subjected
25 to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure. The residue was subjected to a silica gel column chromatography. From the fractions eluted with chloroform-methanol (50:1, v/v), was obtained ethyl 3-[4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]-2-cyanopropionate (2.25 g, quant.) as an oily product.
NMR(δ ppm in CDCl₃): 1.27(3H,t,J=7Hz), 2.39(3H,s), 3.00(2H,t,J=6.5Hz), 3.12(1H,dd,J=14&8Hz), 3.22(1H,dd,J=14&6Hz),
30 3.66(1H,dd,J=8&6Hz), 4.22(2H,q,J=7Hz), 4.24(2H,t,J=6.5Hz), 6.87(2H,d,J=9Hz), 7.17(2H,d,J=9Hz), 7.25-7.5(3H,m), 7.85-8.0(1H,m).

Reference Example 31

- 35 **[0088]** A mixture of ethyl 3-[4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]-2-cyanopropionate (2.24 g), 1N NaOH (15 ml) and ethanol (50 ml) was stirred for one hour at room temperature. The reaction mixture was poured into water and made acidic, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure to leave a crystalline product, which was added to pyridine (5 ml) - o-dichlorobenzene (50 ml), and the mixture was heated for 2 hours under reflux.
40 The reaction mixture was concentrated under reduced pressure, which was subjected to a silica gel column chromatography. From the fractions eluted with chloroform was obtained 3-[4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]propionitrile (1.5 g, 80%), which was recrystallized from dichloromethane - isopropyl ether to give pale yellow crystals, m.p.88-89°C.

45 Reference Example 32

- [0089]** In substantially the same manner as in Reference Example 22, was obtained ethyl 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)cinnamate, which was recrystallized from ethyl acetate - hexane to give colorless prisms, m.p. 145-146°C.

50

Reference Example 33

- [0090]** In substantially the same manner as in Reference Example 23, was obtained (E)-3-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]-2-propen-1-ol, which was recrystallized from ethyl acetate - hexane to give colorless
55 prisms, m.p.134-135°C.

Reference Example 34

5 **[0091]** Activated manganese dioxide (MnO_2) (9.0 g) was added to a solution of (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-propen-1-ol (3.7 g) in dichloromethane (80 ml), which was stirred for one hour at room temperature. The reaction mixture was subjected to filtration through celite layer. The filtrate was concentrated under reduced pressure to give 4-(5-methyl-2-phenyl-4-oxazolymethoxy)-cinnamoaldehyde (2.6 g, 70%), which was recrystallized from ethyl acetate - hexane to yield colorless prisms, m.p. 114-115°C.

Reference Example 35

10 **[0092]** Sodium hydride (60% in oil, 0.32 g) was added, in small portions at 0°C, to a solution of diethyl cyanomethylphosphonate (1.3 g) in tetrahydrofuran (50 ml). The mixture was stirred for 15 minutes at the same temperature, to which was then added 4-(5-methyl-2-phenyl-4-oxazolymethoxy)cinnamoaldehyde (2.0 g), followed by stirring for 30 minutes under ice-cooling. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO_4), which was then concentrated to give (E, E)-5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2,4-pentadienenitrile (1.5 g, 68%). Recrystallization of the product from ethyl acetate - hexane afforded colorless needles, m.p. 120-121°C.

Reference Example 36

20 **[0093]** In substantially the same manner as in Reference Example 24, was obtained 3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]propan-1-ol, which was recrystallized from ethyl acetate - hexane to yield colorless prisms, m.p. 72-73°C.

Reference Example 37

25 **[0094]** In substantially the same manner as in Reference 25, was obtained 3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]propyl bromide, which was recrystallized from ethyl ether - hexane to yield colorless prisms, m.p. 80-81°C.

Reference Example 38

30 **[0095]** A mixture of 3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]propyl bromide (1.5 g), powdered potassium cyanide (1.52 g) and N,N-dimethylformamide (30 ml) was stirred for 3 hours at 80°C. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO_4), which was then concentrated to give 4-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]butyronitrile (1.2 g, 92%). Recrystallization of the product from ethyl acetate - hexane gave colorless needles, m.p. 73-74°C.

Reference Example 39

40 **[0096]** In substantially the same manner as in Reference Example 38, 4-[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]butyronitrile, which was recrystallized from ethyl ether - hexane to yield colorless needles, m.p. 69-70°C.

Reference Example 40

45 **[0097]** According to the method described for Reference Example 22, 4-(5-methyl-2-phenyl-4-oxazolymethoxy)cinnamoaldehyde was allowed to react with triethyl phosphonoacetate to give ethyl (E,E)-5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2, 4-pentadienoate, followed by recrystallization from ethyl acetate - hexane to give colorless prisms, m.p. 137-138°C.

Reference Example 41

50 **[0098]** According to the method described for Reference Example 16, ethyl (E,E)-5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2,4-pentadienoate was subjected to catalytic hydrogenation to give ethyl 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]valerate. Recrystallization from hexane gave colorless rods, m.p. 57-58°C.

Reference Example 42

55 **[0099]** A solution of ethyl 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]valerate (2.55 g) in ether (20 ml) was

added dropwise, under ice-cooling, to a suspension of lithium aluminum hydride (LiAlH_4) (0.247 g) in ether (40 ml). The mixture was stirred for 15 minutes under ice-cooling, to which was added water (2 ml). Insoluble solid was filtered off, and the filtrate was concentrated to give 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-1-pentanol (2.15 g, 94%), which was recrystallized from ethyl acetate - hexane to give colorless rods, m.p. 78-79°C.

5

Reference Example 43

[0100] According to the method described for Reference Example 25, 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-1-pentanol was allowed to react with phosphorus tribromide to give 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]pentyl bromide. Recrystallization from ether-hexane gave colorless needles, m.p. 58-59°C.

10

Reference Example 44

[0101] According to the method described for Reference Example 38, 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]pentyl bromide was allowed to react with potassium cyanide to give 5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]hexanenitrile. Recrystallization from ether-hexane afforded colorless prisms, m.p. 76-77°C.

15

Reference Example 45

[0102] A mixture of 4-chloromethyl-5-methyl-2-phenyloxazole (9.2 g), p-hydroxyacetophenone (7.95 g), potassium carbonate (6.73 g) and N,N-dimethylformamide (DMF) (100 ml) was stirred for 2.5 hours at temperatures ranging from 70 to 80°C. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, and dried (MgSO_4), then the solvent was distilled off to give 4'-(5-methyl-2-phenyl-4-oxazolymethoxy)acetophenone (11.6 g, 85%). Recrystallization from ethyl acetate - ether gave colorless prisms, m.p. 126-127°C.

25

Reference Example 46

[0103] According to the method described for Reference Example 22, 4'-(5-methyl-2-phenyl-4-oxazolymethoxy)acetophenone was allowed to react with trimethyl phosphonoacetate to give methyl (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-ol. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p. 125-126°C.

30

Reference Example 47

[0104] According to the method described for Reference Example 23, methyl (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-ol was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-ol. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p. 126-127°C.

35

Reference Example 48

[0105] According to the method described for Reference Example 34, (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-ol was subjected to oxidation with activated manganese dioxide to give (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-al. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p. 94-95°C.

45

Reference Example 49

[0106] According to the method described for Reference Example 35, (E)-3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-buten-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2,4-hexadienenitrile. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p. 134-136°C.

50

Reference Example 50

55

[0107] According to the method described for Reference Example 45, 4-chloromethyl-5-methyl-2-phenyloxazole was allowed to react with m-hydroxybenzaldehyde to give 3-(5-methyl-2-phenyl-4-oxazolymethoxy)benzaldehyde. Recrystallization from ethanol gave colorless prisms, m.p. 67-68°C.

Reference Example 51

5 [0108] According to the method described for Reference Example 22, 3-(5-methyl-2-phenyl-4-oxazolymethoxy)benzaldehyde was allowed to react with triethyl phosphonoacetate to give ethyl 3-(5-methyl-2-phenyl-4-oxazolymethoxy) cinnamate. Recrystallization from ethanol gave colorless prisms, m.p.94-95°C.

Reference Example 52

10 [0109] According to the method described for Reference Example 23, ethyl 3-(5-methyl-2-phenyl-4-oxazolymethoxy) cinnamate was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[3-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-propen-1-ol. Recrystallization from ethyl acetate gave colorless prisms, m.p.120-121°C.

Reference Example 53

15 [0110] According to the method described for Reference Example 34, (E)-3-[3-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-propen-1-ol was subjected to oxidation with activated manganese dioxide to give (E)-3-[3-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-propen-1-al. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p.103-104°C.

20 Reference Example 54

[0111] According to the method described for Reference Example 35, (E)-3-[3-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2-propen-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[3-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2,4-pentadienenitrile as an oily product.

25

Reference Example 55

[0112] According to the method described for Reference Example 45, 2-chloromethyl-5-methyl-4-phenylthiazole was allowed to react with p-hydroxybenzaldehyde to give 4-(5-methyl-4-phenyl-2-thiazolymethoxy)benzaldehyde. Recrystallization from ethyl acetate - isopropyl ether gave colorless prisms, m.p.81-82°C.

30

Reference Example 56

35 [0113] According to the method described for Reference Example 22, 4-(5-methyl-4-phenyl-2-thiazolymethoxy)benzaldehyde was allowed to react with trimethyl phosphonoacetate to give methyl 4-(5-methyl-4-phenyl-2-thiazolymethoxy) cinnamate. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p.142-143°C.

Reference Example 57

40 [0114] According to the method described for Reference Example 23, methyl 4-(5-methyl-4-phenyl-2-thiazolymethoxy) cinnamate was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[4-(5-methyl-4-phenyl-2-thiazolymethoxy)phenyl]-2-propen-1-ol. Recrystallization from ethyl acetate - isopropyl ether gave colorless prisms, m.p.125-126°C.

45 Reference Example 58

[0115] According to the method described for Reference Example 34, (E)-3-[4-(5-methyl-4-phenyl-2-thiazolymethoxy)phenyl]-2-propen-1-ol was subjected to oxidation reaction with activated manganese dioxide to give (E)-3-[4-(5-methyl-4-phenyl-2-thiazolymethoxy)phenyl]-2-propen-1-al. Recrystallization from ethyl acetate - hexane gave colorless prisms, m.p.116-117°C.

50

Reference Example 59

55 [0116] According to the method described for Reference Example 35, (E)-3-[4-(5-methyl-4-phenyl-2-thiazolymethoxy)phenyl]-2-propen-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[4-(5-methyl-4-phenyl-2-thiazolymethoxy)phenyl]-2,4-pentadienenitrile. Recrystallization from ethyl acetate - ether gave colorless prisms, m.p.108-109°C.

Reference Example 60

5 [0117] According to the method described for Reference Example 45, 2-chloromethyl-5-methyl-4-phenyloxazole was allowed to react with p-hydroxybenzaldehyde to give 4-(5-methyl-4-phenyl-2-oxazolymethoxy)benzaldehyde. Recrystallization from ethyl acetate - isopropyl ether gave colorless prisms, m.p.90-91°C.

Reference Example 61

10 [0118] According to the method described for Reference Example 22, 4-(5-methyl-4-phenyl-2-oxazolymethoxy)benzaldehyde was allowed to react with trimethyl phosphonoacetate to give methyl 4-(5-methyl-4-phenyl-2-oxazolymethoxy)cinnamate. Recrystallization from ethyl acetate - isopropyl ether gave colorless prisms, m.p.109-110°C.

Reference Example 62

15 [0119] According to the method described for Reference Example 23, methyl 4-(5-methyl-4-phenyl-2-oxazolymethoxy)cinnamate was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2-propen-1-ol. Recrystallization from chloroform-isopropyl ether gave colorless prisms, m.p. 154-155°C.

20 Reference Example 63

25 [0120] According to the method described for Reference Example 34, (E)-3-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2-propen-1-ol was subjected to oxidation with activated manganese dioxide to give (E)-3-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2-propen-1-al. Recrystallization from chloroform ether gave colorless prisms, m.p.144-146°C.

Reference Example 64

30 [0121] According to the method described for Reference Example 35, (E)-3-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2-propen-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2,4-pentadienenitrile. Then, according to the method described for Reference Example 16, (E,E)-5-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]-2,4-pentadienenitrile was subjected to catalytic reduction to give 5-[4-(5-methyl-4-phenyl-2-oxazolymethoxy)phenyl]valeronitrile. Recrystallization from ethyl acetate - ether - hexane gave colorless prisms, m.p.65-66°C.

35

Reference Example 65

40 [0122] According to the method described for Reference Example 45, 4-chloromethyl-5-methyl-2-(2-naphthyl)oxazole was allowed to react with p-hydroxybenzaldehyde to give 4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]benzaldehyde. Recrystallization from chloroform-ether gave colorless prisms, m.p.163-164°C.

Reference Example 66

45 [0123] According to the method described for Reference Example 22, 4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]benzaldehyde was allowed to react with trimethyl phosphonoacetate to give methyl 4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]cinnamate. Recrystallization from chloroform-ether gave colorless prisms, m.p.185-186°C.

Reference Example 67

50 [0124] According to the method described for Reference Example 23, methyl 4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]cinnamate was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]phenyl]-2-propen-1-ol. Recrystallization from chloroform-ether gave colorless prisms, m.p. 159-160°C.

55 Reference Example 68

[0125] According to the method described for Reference Example 34, (E)-3-[4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]phenyl]-2-propen-1-ol was subjected to oxidation with activated manganese dioxide to give (E)-3-[4-[5-methyl-

2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]-2-propen-1-al. Recrystallization from chloroform-ether gave colorless prisms, m.p.179-180°C.

Reference Example 69

[0126] According to the method described for Reference Example 35, (E)-3-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]-2-propen-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]-2,4-pentadienenitrile. Recrystallization from ethyl acetate - ether gave colorless prisms, m.p.159-160°C.

Reference Example 70

[0127] According to the method described for Reference Example 45, 4-chloromethyl-5-methyl-2-(2-naphthyl)oxazole was allowed to react with 4-(4-hydroxyphenyl)butyronitrile to give 4-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]butyronitrile. Recrystallization from chloroform-ether gave colorless prisms, m.p.149-151°C.

Reference Example 71

[0128] According to the method described for Reference Example 45, 4-chloromethyl-5-methyl-3-(2-naphthyl)oxazole was allowed to react with methyl 5-(4-hydroxyphenyl)valerate to give methyl 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]valerate. Then, according to the method described for Reference Example 42, methyl 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]valerate was subjected to reduction with lithium aluminum hydride to give 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]pentan-1-ol. Recrystallization from ethyl acetate - ether gave colorless needles, m.p.128-129°C.

Reference Example 72

[0129] To a mixture of 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]pentan-1-ol (1.1 g), triethylamine (0.333 g) and dichloromethane (40 ml) was added dropwise, under ice-cooling, methanesulfonyl chloride (0.345 g). The mixture was stirred for 2 hours at room temperature, which was washed with water and dried (MgSO₄). The solvent was distilled off to leave 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]pentyl methanesulfonate (1.21 g, 92%). Recrystallization from dichloromethane-ether gave colorless prisms, m.p.132-133°C.

Reference Example 73

[0130] According to the method described for Reference Example 38, 5-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]pentyl methanesulfonate was allowed to react with potassium cyanide to give 6-[4-[5-methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]hexanenitrile. Recrystallization from ethyl acetate - isopropyl ether gave colorless prisms, m.p.116-117°C.

Reference Example 74

[0131] According to the method described for Reference Example 35, 4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]benzaldehyde was allowed to react with diethyl cyanomethylphosphonate to give 4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]cinnamitrile. Recrystallization from ethyl acetate - isopropyl ether - hexane gave colorless prisms, m.p. 97-98°C.

Reference Example 75

[0132] According to the method described for Reference Example 45, 2-chloromethyl-5-methyl-4-phenyloxazole was allowed to o-hydroxybenzaldehyde to give 2-(5-methyl-4-phenyl-2-oxazolylmethoxy)benzaldehyde. Recrystallization from ethyl acetate - ether gave colorless prisms, m.p.95-96°C.

Reference Example 76

[0133] According to the method described for Reference Example 22, 2-(5-methyl-4-phenyl-2-oxazolylmethoxy)benzaldehyde was allowed to react with trimethyl phosphonoacetate to give methyl 2-(5-methyl-4-phenyl-2-oxazolylmethoxy)cinnamate. Recrystallization from ethyl acetate - chloroform-ether gave colorless prisms, m.p.128-129°C.

Reference Example 77

5 **[0134]** According to the method described for Reference Example 23, methyl 2-(5-methyl-4-phenyl-2-oxazolylmethoxy)cinnamate was subjected to reduction with diisobutylaluminum hydride to give (E)-3-[2-(5-methyl-4-phenyl-2-oxazolylmethoxy)phenyl]-2-propen-1-ol. Recrystallization from ethyl acetate-ether gave colorless prisms, m.p. 128-129°C.

Reference Example 78

10 **[0135]** According to the method described for Reference Example 34, (E)-3-[2-(5-methyl-4-phenyl-2-oxazolylmethoxy)phenyl]-2-propen-1-ol was subjected to oxidation with activated manganese dioxide to give (E)-3-[2-(5-methyl-4-phenyl-2-oxazolylmethoxy)phenyl]-2-propen-1-al. Recrystallization from chloroform - isopropyl ether gave colorless prisms, m.p. 112-113°C.

15 Reference Example 79

[0136] According to the method described for Reference Example 35, (E)-3-[2-(5-methyl-4-phenyl-2-oxazolylmethoxy)phenyl]-2-propen-1-al was allowed to react with diethyl cyanomethylphosphonate to give (E,E)-5-[2-(5-methyl-4-phenyl-2-oxazolylmethoxy)phenyl]-2,4-pentadienenitrile. Recrystallization from ethanol-chloroform gave colorless
20 prisms, m.p. 128-129°C.

Reference Example 80

[0137] According to the method described for Reference Example 45, 2-(benzo[b]furan-2-yl)-4-chloromethyl-5-methyloxazole was allowed to react with 4-(4-hydroxyphenyl)butyronitrile to give 4-[4-[2-(benzo[b]furan-2-yl)-5-methyl-4-oxazolylmethoxy]phenyl]butyronitrile. Recrystallization from dichloromethane - isopropyl ether gave colorless prisms,
25 m.p. 118-119°C.

Reference Example 81

30 **[0138]** According to the method described for Reference Example 45, 4-chloromethyl-2-(furan-2-yl)-5-methyloxazole was allowed to react with 4-(4-hydroxyphenyl)butyronitrile to give 4-[4-[2-(furan-2-yl)-5-methyl-4-oxazolylmethoxy]phenyl]butyronitrile as an oily product. NMR(δ ppm in CDCl_3): 1.85-2.05(2H,m), 2.31(2H,t,J=7Hz), 2.42(3H,s), 2.72(2H,t,J=7.5Hz), 4.97(2H,s), 6.52(1H,dd,J=3.5&2Hz), 6.9-7.0(3H,m), 7.10(2H,d,J=9Hz), 7.53(1H,dd,J=2&1Hz).
35

Reference Example 82

[0139] According to the method described for Reference Example 45, 3-chloromethyl-1-methyl-5-phenyl-1,2,4-triazole was allowed to react with 4-(4-hydroxyphenyl)butyronitrile to give 4-[4-(1-methyl-5-phenyl-1,2,4-triazol-3-ylmethoxy)phenyl]butyronitrile. Recrystallization from dichloromethane-isopropyl ether gave colorless prisms, m.p. 106-107°C.
40

Reference Examples 83

45 **[0140]** In substantially the same manner as in Reference Example 1, 2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-nitropyridine was obtained by reacting 2-chloro-5-nitropyridine with 5-methyl-2-phenyl-4-oxazolylmethanol. The yield was 84 %. Recrystallization from dichloromethane-isopropyl ether gave pale yellow prisms, m.p. 142-143°C.

Reference Example 84

50 **[0141]** In substantially the same manner as in Reference Example 2, 5-amino-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine was obtained by subjecting 2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-nitropyridine to catalytic hydrogenation. The yield was 81 %. Recrystallization from methanol-isopropyl ether gave colorless prisms, m.p. 106-107°C.

55 Reference Example 85

[0142] To a mixture of 5-amino-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine (4.00 g), 47 % HBr (12.2 g) and acetone (80 ml) was added dropwise a solution of sodium nitrite (NaNO_2) (1.08 g) in water (2 ml) at temperatures

below 5°C. After stirring for 30 minutes, methyl acrylate (6.12 g) was added to the mixture, and then copper (I) oxide (0.20 g) was added at 10 ~ 20°C. The mixture was stirred for further one hour at room temperature, followed by concentration under reduced pressure. The concentrate was diluted with conc. ammonia solution and extracted with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure. The residual oily product was subjected to a silica gel chromatography. From the fractions eluted with ethyl acetate-hexane (1:5, v/v) was obtained 2-bromo-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propionate (2.27 g, 37 %) as an oily substance. NMR(δ ppm in CDCl₃): 2.48(3H,s), 3.18(1H,dd,J=14.5&7Hz), 3.39(1H,dd,J=14.5&8Hz), 3.76(3H,s), 4.34(1H,dd,J=8&7Hz), 5.28(2Hs), 6.78(1H,d,J=8.5Hz), 7.35-7.5(4H,m), 7.95-8.1(3H,m).

Reference Example 86

[0143] A mixture of 2-bromo-3-[2-(5-methyl-2-phenyl-4-oxazolyl-methoxy)-5-pyridyl]propionate (4.00 g), 1,8-diazabicyclo[5,4,0]-7-undecene (1.41 g) and toluene (80 ml) was stirred 2 hours at 90-100°C. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water and dried (MgSO₄), then the solvent was distilled off under reduced pressure. The residual oily product was subjected to a silica gel chromatography. From the fractions eluted with ethyl acetate-hexane (1:3, v/v) was obtained methyl (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]acrylate (2.71 g, 83 %). Recrystallization from diethyl ether-isopropyl ether gave colorless prisms, m.p. 116-117°C.

Reference Example 87

[0144] In substantially the same manner as in Reference Example 23, (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]-2-pyridyl-2-propen-1-ol was obtained by reduction of methyl (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]acrylate with diisobutylaluminium hydride. The yield was 76 %. Recrystallization from dichloromethane-isopropyl ether gave colorless prisms, m.p. 116-117°C.

Reference Example 88

[0145] In substantially the same manner as in Reference Example 34, (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]-2-propen-1-al was obtained by oxidation of (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]-2-propen-1-ol with manganese dioxide. The yield was 92 %. Recrystallization from dichloromethane-isopropyl ether gave colorless prisms, m.p. 147-148°C.

Reference Example 89

[0146] In substantially the same manner as in Reference Example 24, 3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propanol was obtained by subjecting (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]-2-propen-1-ol to catalytic hydrogenation. The yield was 82 %. Recrystallization from diethyl ether-isopropyl ether gave colorless needles, m.p. 89-90°C.

Reference Example 90

[0147] In substantially the same manner as in Reference Example 72, 3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propyl methanesulfonate was obtained as an oily product by methanesulfonylation of 3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propanol. The yield was 89 %. NMR(δ ppm in CDCl₃): 1.95-2.15(2H,m), 2.48(3H,s), 2.70(2H,t,J=7.5Hz), 3.01(3H,s), 4.24(2H,t,J=6.5Hz), 5.28(2H,s), 6.78(1H,d,J=8.5Hz), 7.35-7.5(4H,m), 7.95-8.1(3H,m).

Reference Example 91

[0148] In substantially the same manner as in Reference Example 38, 4-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]butyronitrile was obtained as an oily product by reacting 3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propyl methanesulfonate with potassium cyanide. The yield was 95 %. NMR(δ ppm in CDCl₃): 1.85-2.05(2H,m), 2.35(2H,t,J=7Hz), 2.48(3H,s), 2.73(2H,t,J=7.5Hz), 5.28(2H,s), 6.80(1H,d,J=8.5Hz), 7.35-7.5(4H,m), 7.95-8.1(3H,m).

Reference Example 92

[0149] In substantially the same manner as in Reference Example 64, 5-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-

EP 0 629 624 B1

5-pyridyl]valeronitrile was obtained as an oily product by reacting (E)-3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]-2-propen-1-al with diethyl cyanomethylphosphonate, followed by catalytic hydrogenation. The yield was 96 %. NMR(δ ppm in CDCl_3): 1.55-1.85(4H,m), 2.37(2H,t,J=6.5Hz), 2.48(3H,s), 2.59(2H,t,J=7.5Hz), 5.27(2H,s), 6.77(1H,d,J=8.5Hz), 7.35-7.5(4H,m), 7.95-8.1(3H,m).

5

Example 1

[0150] A mixture of 3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionitrile (0.7 g), sodium azide (0.411 g), ammonium chloride (0.337 g) and N,N-dimethylformamide (15 ml) was stirred for 24 hours at 120°C. The reaction mixture was poured into water, which was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and dried, then the solvent was distilled off to leave 5-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]tetrazole (0.38 g, 48%), which was recrystallized from ethyl acetate - hexane to give colorless prisms, m.p. 143-144°C.

10

15

Examples 2 to 14

[0151] In substantially the same manner as in Example 1, compounds shown in [Table 4] and [Table 5] were obtained.

20

25

30

35


40

45

50


55

Table 4



| Example No. | A | n | X | Y | Yield (%) | Melting point (°C) | Recrystallization Solvent |
|-------------|---|---|----|--|-----------|--------------------|-------------------------------------|
| 2 | | 2 | N | -CH ₂ CH ₂ - | 44 | 143-144 | ethanol |
| 3 | | 2 | N | (E) -CH=CH- | 21 | 195-196 | ethyl acetate |
| 4 | | 2 | CH | -CH ₂ CH ₂ - | 43 | 124-125 | dichloromethane- ethyl acetate |
| 5 | | 2 | CH | -CH ₂ CH ₂ - | 81 | 80- 81 | dichloromethane- isopropyl ether |
| 6 | | 2 | CH | -CH ₂ - | 56 | 173-174 | methanol |
| 7 | | 2 | CH | -CH ₂ CH ₂ CH ₂ - | 56 | 124-125 | ethyl acetate- hexane |
| 8 | | 2 | CH | -CH ₂ CH ₂ - | 47 | 143-144 | methanol |
| 9 | | 2 | CH | -CH ₂ CH ₂ - | 89 | 141-142 | dichloromethane- ethyl acetate |
| 10 | | 1 | CH | -CH ₂ CH ₂ - | 45 | 140-141 | methanol- ethyl acetate |

[Table 5]



| Example No. | A | n | X | Y | Yield (%) | Melting point (°C) | Recrystallization Solvent |
|-------------|---|---|----|--|-----------|--------------------|---------------------------|
| 1 1 | | 2 | CH | -CH ₂ CH ₂ - | 45 | Note 1) 225-226 | methanol-ether |
| 1 2 | | 1 | CH | (E) -CH=CH- | 85 | 214-215 | methanol-chloroform |
| 1 3 | | 1 | CH | (E) -CH=CH- (E) -CH=CH- | 57 | 203-204 | methanol |
| 1 4 | | 1 | CH | -CH ₂ CH ₂ CH ₂ - | 25 | 107-108 | ethyl acetate-hexane |

¹⁾ sodium salt

| Elemental analysis: calculated for C ₁₆ H ₁₆ N ₅ O ₂ Na·1/2 H ₂ O | | | |
|--|-----------|----------|----------|
| | C, 55.81; | H, 5.56; | N, 20.34 |
| Found | C, 56.01; | H, 5.82; | N, 20.68 |

Example 15

[0152] A mixture of (E)-5-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)styryl]tetrazole (1.0 g), palladium-carbon (5%, 0.5 g) and dioxane (100 ml) was subjected to catalytic hydrogenation at room temperature. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to give 5-[2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]ethyl]-tetrazole (0.81 g, 81%), which was recrystallized from methanol-chloroform to yield colorless plates, m.p. 203-204°C.

Example 16


[0153] In substantially the same manner as in Example 15, 5-[4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]-1,3-butadien-1-yl]tetrazole was subjected to catalytic hydrogenation to yield 5-[4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]butyl]tetrazole, which was recrystallized from ethyl acetate - hexane to give colorless prisms, m.p. 116-117°C.

Examples 17-27

[0154] By a similar manner to Example 1, compounds shown in Table 6 and Table 7 were obtained.







Table 6

(wherein X is C-H)



| Example No. | A | n | Y | Melting point (°C) | Yield (%) | Recrystallization Solvent |
|-------------|---|---|---------------------------------|--------------------|-----------|----------------------------|
| 17 | | 1 | $-(CH_2)_3-CH=CH-CH=CH-$ (E) | 200-201 | 28 | chloroform-methanol-ether |
| 18 | | 1 | $-(CH_2)_5-$ | 129-130 | 46 | ethyl acetate-hexane |
| 19 | | 1 | $-(CH_2)_3-CH=CH-CH=CH-$ (E) | 226-227 | 33 | chloroform-methanol |
| 20 | | 1 | $-(CH_2)_4-$ | 126-127 | 13 | chloroform-isopropyl ether |
| 21 | | 1 | $-(CH_2)_3-CH=CH-CH=CH-$ (E) | 162-163 | 20 | chloroform-methanol |

Table 7

| Example No. | A | n | γ | Melting point (°C) | Yield (%) | Recrystallization Solvent |
|-------------|---|---|---------------|--------------------|-----------|---------------------------------|
| 2 2 |  | 1 | $-(CH_2)_3-$ | 156-157 | 2 9 | dichloromethane-ether |
| 2 3 |  | 1 | $-(CH_2)_2-$ | 139-140 | 2 3 | chloroform-ether |
| 2 4 |  | 3 | $-(E)-CH=CH-$ | 185-186 | 4 0 | chloroform-methanol |
| 2 5 |  | 1 | $-(CH_2)_3-$ | 121-122 | 4 6 | dichloromethane-isopropyl ether |
| 2 6 |  | 1 | $-(CH_2)_3-$ | 133-134 | 4 4 | dichloromethane-isopropyl ether |
| 2 7 |  | 1 | $-(CH_2)_3-$ | 159-160 | 8 3 | dichloromethane-methanol |

Example 28

[0155] According to the method described for Example 1, (E,E)-5-[3-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]-2,4-pentadienenitrile was allowed to react with sodium azide -ammonium chloride to give 5-[4-[3-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]-1,3-butadien-1-yl]tetrazole. Recrystallization from methanol gave colorless prisms, m.p.

201-202°C.

Example 8

5 [0156] According to the method described for Example 1, (E,E)-5-[2-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-2,4-pentadienenitrile was allowed to react with sodium azide-ammonium chloride to give 5-[4-[2-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]-1,3-butadien-1-yl]tetrazole. Recrystallization from dichloromethane-methanol gave colorless prisms, m.p. 192-193°C.

10 Example 29 to Example 34

[0157] According to the method described Example 15, compounds set forth in [Table 8] were produced.

Table 8

| Example No. | | Melting point (°C) | Yield (%) | Recrystallization Solvent |
|-------------|--|--------------------|-----------|---------------------------|
| 30 | | 94-95 | 81 | ethyl acetate-hexane |
| 31 | | 41 | 41 | — |
| 32 | | 126-127 | 43 | ethyl acetate-ether |
| 33 | | 162-164 | 62 | ethyl acetate-ether |
| 34 | | 148-149 | 55 | dichloromethane-methanol |
| 35 | | 112-113 | 14 | chloroform-ether |

1) oil. NMR (δ ppm in CDCl_3): 1.15(3H,d, $J=7\text{Hz}$), 1.35-1.85(4H,m), 2.47(3H,s), 2.47-2.68(1H,m), 2.68-2.95(2H,m), 4.91(2H,s), 6.73(2H,d, $J=8.8\text{Hz}$), 6.92(2H,d, $J=8.8\text{Hz}$), 7.35-7.52(3H,m), 7.90-8.05(2H,m).

Example 36

[0158] In substantially the same manner as in Example 1, 5-[3-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]propyl]-1H-tetrazole was obtained by reacting 4-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]butyronitrile with sodium azide-ammonium chloride. The yield was 45 %. Recrystallization from methanol-ethyl acetate gave colorless prisms, m.p. 137-138°C.

Example 37

[0159] In substantially the same manner as in Example 1, 5-[4-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]butyl]-1H-tetrazole was obtained by reacting 5-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridyl]valeronitrile with sodium azide-ammonium chloride. The yield was 46 %. Recrystallization from ethyl acetate-hexane gave colorless prisms, m.p. 104-105°C.

| Formulation Example 1 (Preparation of tablets) | | |
|--|--|-------|
| (1) 5-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]phenyl]ethyl]tetrazole (Compound produced in Example 1) | | 10 g |
| (2) lactose | | 50 g |
| (3) corn starch | | 15 g |
| (4) carboxymethyl cellulose calcium | | 44 g |
| (5) magnesium stearate | | 1 g |
| 1000 tablets | | 120 g |

[0160] The whole amounts of above (1), (2) and (3), and 30 g of (4) were kneaded with water, which was subjected to vacuum drying, followed by granulation.


[0161] Thus-granulated powder was mixed with 14 g of (4) and 1 g of (5), followed by tableting using a tableting machine to prepare 1000 tablets containing 10 mg of (1) per tablet.

| Formulation Example 2 (Preparation of tablets) | | |
|--|--|-------|
| (1) | 5-[3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]tetrazole (Compound produced in Example 7) | 30 g |
| (2) | Lactose | 50 g |
| (3) | corn starch | 15 g |
| (4) | carboxymethyl cellulose calcium | 44 g |
| (5) | magnesium stearate | 1 g |
| | 1000 tablets | 140 g |

[0162] The whole amounts of above (1), (2) and (3), and 30 g of (4) were kneaded with water, which was subjected to vacuum drying, followed by granulation. Thus-granulated powder was mixed with 14 g of (4) and 1 g of (5), which was tableted by using a tableting machine to prepare 1000 tablets containing 30 mg of (1) per tablet.


Claims

1. A compound of the formula:




10 wherein n denotes an integer of 1 to 3;

A is an aromatic 5-membered cyclic residue shown by the formula:



20 wherein B¹ is S, O or NR (wherein R is hydrogen, a C₁₋₃ alkyl group or an aralkyl group selected from benzyl or phenethyl); B² is N or C-R² (R² is hydrogen or a C₁₋₅ alkyl group optionally substituted with hydroxyl group; R¹ is hydrogen; hydrocarbon residue selected from C₁₋₈ saturated aliphatic hydrocarbon residues, C₂₋₈ unsaturated aliphatic hydrocarbon residues, C₃₋₇ saturated alicyclic hydrocarbon residues, C₅₋₇ unsaturated alicyclic hydrocarbon residues, C₄₋₉ alicyclic-aliphatic hydrocarbon residues, C₇₋₉ aromatic-aliphatic hydrocarbon residues, aromatic hydrocarbon residues, selected from phenyl and naphthyl; or a heterocyclic residue selected from a 5- or 6-membered ring which contains, besides carbon atoms, 1 to 3 atoms selected from N, O and S as atoms constituting the ring, which is bonded through a carbon atom; wherein, when the hydrocarbon residue contains an alicyclic group or when the heterocyclic residue is a saturated one, each of them may have 1 to 3 C₁₋₃ alkyl groups on the ring thereof; and when the hydrocarbon residue contains an aromatic group or when the heterocyclic residue is an unsaturated one, it may have 1 to 4 substituents selected from halogen, hydroxyl, cyano, nitro, trifluoromethyl, a C₁₋₄ alkoxy group, a C₁₋₄ alkyl group, a C₂₋₄ alkoxy carbonyl group, a C₁₋₃ alkylthio and a C₁₋₄ alkylamino group;
 25 Y is -CH₂CH₂CH₂- or -CH₂CH₂CH₂CH₂-; and
 30 X is CH or N,
 35 or a pharmaceutically acceptable salt thereof.

40 2. A compound as claimed in Claim 1, wherein A is a group shown by the formula:




50 wherein R¹ and R² are as defined in claim 1; B is O or S, or a pharmaceutically acceptable salt thereof.

3. A compound as claimed in claim 1, wherein B¹ is S, O or NR (wherein R is hydrogen, a C₁₋₃ alkyl group or an aralkyl group selected from benzyl and phenethyl), and B² is N, or a pharmaceutically acceptable salt thereof.

55 4. A compound as claimed in claim 1, wherein n is 1 or 2, or a pharmaceutically acceptable salt thereof.

5. A compound as claimed in claim 1, wherein X is CH, or a pharmaceutically acceptable salt thereof.


6. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]propyl]tetrazole or a pharmaceutically acceptable salt thereof.
7. A compound as claimed in claim 1, wherein the compound is 5-[4-[4-(5-methyl-2-phenyl-4-oxazolymethoxy)phenyl]butyl]tetrazole or a pharmaceutically acceptable salt thereof.
8. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-[5-methyl-2-(2-naphthyl)-4-oxazolymethoxy]phenyl]propyl]tetrazole or a pharmaceutically acceptable salt thereof.
9. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-[5-methyl-2-(2-furyl)-4-oxazolymethoxy]phenyl]propyl]tetrazole or a pharmaceutically acceptable salt thereof.
10. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-(1-methyl-5-phenyl-1,2,4-triazol-3-ylmethoxy)phenyl]propyl]tetrazole or a pharmaceutically acceptable salt thereof.
11. A compound as claimed in claim 1, wherein the compound is 5-[3-[4-[5-methyl-2-(benzo [b] furan-2-yl)-4-oxazolymethoxy]phenyl]propyl]tetrazole or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a compound of the formula according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
13. Use of a compound of the formula according to claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a mammal suffering from diabetes.
14. Use of a compound of the formula according to claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a mammal suffering from hyperlipemia.
15. A method of producing a compound of the formula according to claim 1, which comprises allowing the compound of the formula:



wherein each symbol is of the same meaning as defined in claim 1 to react with a metal azide compound.


Patentansprüche

1. Verbindung der Formel:



in der n eine ganze Zahl von 1 bis 3 bezeichnet;

A ein aromatischer, fünfgliedriger cyclischer Rest ist, der durch die Formel:




dargestellt wird, in der

B¹ S, O oder NR (wobei R Wasserstoff, eine C₁₋₃-Alkylgruppe oder eine Aralkylgruppe ist, die aus Benzyl oder Phenethyl ausgewählt ist) ist; B² N oder C-R² ist (R² Wasserstoff oder eine C₁₋₅-Alkylgruppe ist, die gegebenenfalls mit einer Hydroxylgruppe substituiert ist); R¹ folgendes ist: Wasserstoff, ein Kohlenwasserstoffrest, der ausgewählt ist aus gesättigten, aliphatischen C₁₋₈-Kohlenwasserstoffresten, ungesättigten, aliphatischen C₂₋₈-Kohlenwasserstoffresten, gesättigten, alicyclischen C₃₋₇-Kohlenwasserstoffresten, ungesättigten, alicyclischen C₅₋₇-Kohlenwasserstoffresten, alicyclisch-aliphatischen C₄₋₉-Kohlenwasserstoffresten, aromatisch-aliphatischen C₇₋₉-Kohlenwasserstoffresten, aromatischen Kohlenwasserstoffresten, die aus Phenyl und Naphthyl ausgewählt sind; oder ein heterocyclischer Rest, der aus einem fünf- oder sechsgliedrigen Ring ausgewählt ist, der neben Kohlenstoffatomen 1 bis 3 Atome, die aus N, O und S ausgewählt sind, als Atome enthält, die den Ring ausmachen, der durch ein Kohlenstoffatom gebunden ist; wobei, wenn der Kohlenwasserstoffrest eine alicyclische Gruppe enthält, oder wenn der heterocyclische Rest ein gesättigter Rest ist, jeder derselben 1 bis 3 C₁₋₃-Alkylgruppen am Ring aufweisen kann; und wenn der Kohlenwasserstoffrest eine aromatische Gruppe enthält, oder wenn der heterocyclische Rest ein ungesättigter Rest ist, derselbe 1 bis 4 Substituenten aufweisen kann, die aus Halogen, Hydroxyl, Cyano, Nitro, Trifluormethyl, einer C₁₋₄-Alkoxygruppe, einer C₁₋₄-Alkylgruppe, einer C₂₋₄-Alkoxycarbonylgruppe, einer C₁₋₃-Alkythio- und einer C₁₋₄-Aminogruppe ausgewählt sind;
Y -CH₂CH₂CH₂- oder -CH₂CH₂CH₂CH₂- ist und
X CH oder H ist,

oder ein pharmazeutisch annehmbares Salz derselben.

2. Verbindung gemäß Anspruch 1, in der A eine Gruppe ist, die durch die Formel



gezeigt wird, in der R¹ und R² wie im Anspruch 1 definiert sind, B O oder S ist; oder ein pharmazeutisch annehmbares Salz derselben.

3. Verbindung gemäß Anspruch 1, in der B¹ S, O oder NR (wobei R Wasserstoff, eine C₁₋₃-Alkylgruppe oder eine Aralkylgruppe ist, die aus Benzyl oder Phenethyl ausgewählt ist) ist, und B² N ist; oder pharmazeutisch annehmbares Salz derselben.
4. Verbindung gemäß Anspruch 1, in der n 1 oder 2 ist; oder pharmazeutisch annehmbares Salz derselben.
5. Verbindung gemäß Anspruch 1, in der X CH ist; oder pharmazeutisch annehmbares Salz derselben.
6. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[3-[4-(5-Methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propyl]tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.
7. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[4-[4-(5-Methyl-2-phenyl-4-oxazolylmethoxy)phenyl]butyl]tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.
8. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[3-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]phenyl]propyl]tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.
9. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[3-[4-[5-Methyl-2-(2-furyl)-4-oxazolylmethoxy]phenyl]pro-

pyl]tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.

10. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[3-[4-(1-Methyl-5-phenyl-1,2,4-triazol-3-ylmethoxy)phenyl]propyl]tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.


11. Verbindung gemäß Anspruch 1, wobei die Verbindung 5-[3-[4-[5-Methyl-2-(benzo[b]furan-2-yl)-4-oxazolylmethoxy]phenyl]propyl]-tetrazol ist; oder pharmazeutisch annehmbares Salz derselben.

12. Pharmazeutische Zusammensetzung, umfassend eine Verbindung der Formel gemäß Anspruch 1 oder ein pharmazeutisch annehmbares Salz derselben zusammen mit einem pharmazeutisch annehmbaren Träger.

13. Verwendung einer Verbindung der Formel gemäß Anspruch 1 oder eines pharmazeutisch annehmbaren Salzes derselben zur Herstellung eines Medikaments zur Behandlung eines an Diabetes leidenden Säugers.

14. Verwendung einer Verbindung der Formel gemäß Anspruch 1 oder eines pharmazeutisch annehmbaren Salzes derselben zur Herstellung eines Medikaments zur Behandlung eines an Hyperlipämie leidenden Säugers.


15. Verfahren zur Herstellung einer Verbindung der Formel gemäß Anspruch 1, umfassend das Reagierenlassen der Verbindung der Formel:



in der jedes Symbol die gleiche wie gemäß Anspruch 1 definierte Bedeutung hat, mit einer Metallazid-Verbindung.

Revendications


1. Composé de formule :



dans laquelle

n représente un nombre entier valant de 1 à 3 ;

A représente un résidu cyclique aromatique à 5 chaînons, représenté par la formule suivante :



dans laquelle

B¹ représente S, O ou NR où R représente un atome d'hydrogène, un groupe alkyle en C₁₋₃ ou un groupe aralkyle choisi parmi les groupes benzyle et phénéthyle,

B² représente N ou CR² où R² représente un atome d'hydrogène ou un groupe alkyle en C₁₋₅ portant éventuellement un substituant hydroxy, et R¹ représente un atome d'hydrogène, un résidu d'hydrocarbure choisi parmi les résidus d'hydrocarbures aliphatiques saturés en C₁₋₆, les résidus d'hydrocarbures aliphatiques in-


saturés en C₂₋₈, les résidus d'hydrocarbures alicycliques saturés en C₃₋₇, les résidus d'hydrocarbures alicycliques insaturés en C₅₋₇, les résidus d'hydrocarbures alicycliques-aliphatiques en C₄₋₉, les résidus d'hydrocarbures aromatiques-aliphatiques en C₇₋₉, et les résidus d'hydrocarbures aromatiques que sont les groupes phényle et naphthyle, ou un résidu hétérocyclique choisi parmi les groupes cycliques à 5 ou 6 chaînons comportant en tant qu'atomes constitutifs du cycle, outre des atomes de carbone, 1 à 3 atomes choisis parmi les atomes d'azote, d'oxygène et de soufre, mais lié par l'intermédiaire d'un atome de carbone ; étant entendu que, si le résidu d'hydrocarbure comporte un groupe alicyclique ou si le résidu hétérocyclique est un résidu saturé, un tel résidu peut dans chaque cas porter sur son cycle 1 à 3 substituants alkyle en C₁₋₃, et que, si le résidu d'hydrocarbure comporte un groupe aromatique ou si le résidu hétérocyclique est un résidu insaturé, un tel résidu peut porter 1 à 4 substituants choisis parmi les atomes d'halogène et les groupes hydroxy, cyano, nitro, trifluorométhyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, alcoxycarbonyle en C₂₋₄, alkylthio en C₁₋₃ et alkylamino en C₁₋₄ ;

Y représente -CH₂CH₂CH₂- ou -CH₂CH₂CH₂CH₂- ;

et X représente CH ou N ;

ou sel, admissible en pharmacie, d'un tel composé.

2. Composé conforme à la revendication 1, dans lequel A représente un groupe de formule



dans laquelle R¹ et R² ont les significations indiquées dans la revendication 1 et B représente O ou S, ou sel, admissible en pharmacie, d'un tel composé.


3. Composé conforme à la revendication 1, dans lequel B¹ représente S, O ou NR où R représente un atome d'hydrogène, un groupe alkyle en C₁₋₃ ou un groupe aralkyle choisi parmi les groupes benzyle et phénéthyle, et B² représente N, ou sel, admissible en pharmacie, d'un tel composé.
4. Composé conforme à la revendication 1, dans lequel n vaut 1 ou 2, ou sel, admissible en pharmacie, d'un tel composé.
5. Composé conforme à la revendication 1, dans lequel X représente CH, ou sel, admissible en pharmacie, d'un tel composé.
6. Composé conforme à la revendication 1, qui est du 5-[3-[4-(5-méthyl-2-phényl-4-oxazolyméthoxy)phényl]propyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
7. Composé conforme à la revendication 1, qui est du 5-[4-[4-(5-méthyl-2-phényl-4-oxazolyméthoxy)phényl]butyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
8. Composé conforme à la revendication 1, qui est du 5-[3-[4-(5-méthyl-2-(2-naphtyl)-4-oxazolyméthoxy)phényl]propyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
9. Composé conforme à la revendication 1, qui est du 5-[3-[4-(5-méthyl-2-(2-furyl)-4-oxazolyméthoxy)phényl]propyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
10. Composé conforme à la revendication 1, qui est du 5-[3-[4-(1-méthyl-5-phényl-1,2,4-triazol-3-ylméthoxy)phényl]propyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
11. Composé conforme à la revendication 1, qui est du 5-[3-[4-(5-méthyl-2-(benzo[b]furan-2-yl)-4-oxazolyméthoxy)phényl]propyl]tétrazole ou l'un de ses sels admissibles en pharmacie.
12. Composition pharmaceutique comprenant un composé de formule conforme à la revendication 1, ou un sel admissible en pharmacie d'un tel composé, ainsi qu'un véhicule admissible en pharmacie.

EP 0 629 624 B1

13. Emploi d'un composé de formule conforme à la revendication 1, ou d'un sel admissible en pharmacie d'un tel composé, pour la fabrication d'un médicament pouvant servir au traitement d'un mammifère souffrant de diabète.

5 14. Emploi d'un composé de formule conforme à la revendication 1, ou d'un sel admissible en pharmacie d'un tel composé, pour la fabrication d'un médicament pouvant servir au traitement d'un mammifère souffrant d'hyperlipémie

10 15. Procédé de préparation d'un composé de formule conforme à la revendication 1, qui comporte le fait de faire réagir, avec un azoture métallique, un composé de formule



15

dans laquelle chaque symbole a la même signification que celle indiquée dans la revendication 1.

20

25

30

35

40

45

50

55